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ABSTRACT 
TARGETED MAGNETITE TISSUE DELIVERY: 
IMPLICATIONS TOWARDS IMPROVING ANTIRETROVIRAL PHARMACOKINETICS 
Tianyuzi Li, Ph.D. 
University of Nebraska Medical Center, 2015 
Supervisor: Howard E Gendelman, M.D.  
Pharmacokinetics and pharmacodynamics studies are required for bench to bedside 
translation of any new drug, formulation or device. Multifunctional magnetite nanocarriers 
enable magnetic resonance imaging tracking of nanomaterial encased antiretroviral 
drugs serving to improve the effectiveness of formulation developments. Targeting 
ligands used to deliver nanoparticles to HIV harboring cells can be tested using 
multifunctional magnetite nanocarriers. To this end, two types of magnetite nanocarriers 
were developed. These included small magnetite antiretroviral therapy particles. The 
second were ALN-PEG coated magnetite particles for testing macrophages targeting 
ligands. Overall, these works should serve to speed the development of long acting 
nanoformulated ART to improve access and effectiveness of treatment regimens for the 
infected human host. 
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1.1. The HIV pandemic 
The first cases of acquired immunodeficiency syndrome (AIDS) were reported in 
1981. Today tens of millions of people have died of AIDS-related causes. At the end of 
2013, there are approximately 35 million people currently living with human 
immunodeficiency virus (HIV), the virus that causes AIDS. HIV has become one of the 
world’s most significant health and development medical challenges. Intensive research 
had been done during the past 34 years. Directed collaborative and aggressive efforts on 
behalf of scientists and physicians worldwide has increased our knowledge of the HIV 
replication cycle, disease pathogenesis, innate and adaptive immunity and antiretroviral 
therapy (ART). 
In 1987, azidothymidine (AZT) became the first approved HIV treatment. Since then, 
approximately 30 drugs were approved for treatment of HIV patients. Nearly a decade 
later, major breakthroughs were made with the introduction of a therapy that combined 
several drugs to limit the viral resistance and limit HIV replication to very low and often 
undetectable levels. Combination ART markedly reduced disease morbidity and mortality 
(1, 2). However, ART can only suppress the replication of HIV and does not eliminate it. 
Thus, new drugs, delivery systems and vaccines are in desperate need if an HIV cure is 
to be achieved.   
 
1.2. HIV virology 
HIV is a 100nm retrovirus including two identical copies of single-stranded RNA. It is a 
highly organized structure consisting of a cylindrical center surrounded by a 
sphere-shaped lipid bilayer where the viral envelope is attached. There are three 
structural genes contain the information needed to make structural proteins for new virus 
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particles: gag which encodes the structural proteins of the core and matrix, env which 
encodes the viral envelope glycoproteins, pol which encodes the viral enzyme (3). 
The basic structure of HIV is as follows (Figure 1):  
- The viral envelope, outer coat of the virus, consists of two layers of lipids: glycoprotein 
(gp) 120 and the transmembrane gp41. Both of the two are encoded by env gene and are 
embedded in the viral envelope where "spikes" are formed. The lipid membrane is taken 
from the host cell during the budding process. 
- The HIV matrix proteins consists of the p17 protein that is encoded by gag gene. They 
lie between the envelope and core.  
- The viral core contains the viral capsid protein p24 which is encoded by gag gene. The 
viral capsid surrounds two single strands of RNA as well as enzymes needed for HIV 
replication, including reverse transcriptase, protease, ribonuclease, and integrase. All the 
enzymes are encoded by pol gene. 
Viral particle membrane is consisting of glycoprotein heterodimer complexes. Gp120 
and transmembrane gp41 are the two major elements in the complex. The function of 
gp120 and gp41 is to mediate host cell recognition, cell attachment as well as cell 
invasion in CD4+ T lymphocytes and monocyte-macrophages (4). Beneath the viral 
lipoprotein membrane, is the matrix protein p17, the core proteins p24 and p6, and the 
nucleocapsid protein p7 which bound to the RNA. The capsid contains viral genome, 
reverse transcriptase, integrase and protease (5). 
HIV virus is also characterized by its accessory/regulatory genes which encode 
proteins with various regulatory or immuno-modulatory functions (6), including tat 
(transactivator of transcription), rev (regulator of viral protein expression), vif (viral 
infectivity protein), vpr (viral protein R) and nef (negative regulatory factor). Among them, 
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tat protein, which promotes the expression of HIV gene, is expressed very early after 
infection. The rev protein ensures the export of the messenger RNA and genomic RNA 
from nucleus to cytoplasm. The function of the other accessory HIV proteins is less well 
understood. 
Previous sequencing studies using samples from HIV infected patients identified that 
HIV virus DNA primarily exist in CD4+T lymphocytes, which suggests that CD4+ T cell is 
the primary target of HIV infection. Subsequent mechanistic studies revealed the life 
cycle of HIV replication in T cells. Before entering cells, the glycoproteins on viral 
envelope target and bind to the CD4 receptor on host cells. This interaction triggers a 
conformational change of viral glycoproteins and facilitate the interaction of virus and 
another two co-receptor on host cells, CCR5 and CXCR4. The interaction with 
co-receptors again triggers a conformational change of viral envelope proteins gp41 and 
enable virus envelope pierces host cells membrane. Next, virus envelope fuses with host 
cell membrane and virus genetic materials and enzymes are injected into host cells, while 
the envelope of HIV is left on the membrane of host cells.  
The genetics materials of virus was coated by a protective viral capsid, which is 
digested in host cells to expose the containing viral RNA as well as key viral enzymes 
such as reverse transcriptase. Reverse transcriptase converts viral RNA into a single 
strand cDNA by using host deoxynucleotides and this process occurs within a complex 
consist of viral capsid and another host cell protein cyclophilin A. The synthesis of viral 
DNA occurs together with the degradation of its template RNA, which is mediated by the 
RNase activity of viral reverse transcriptase. Notably, this reverse transcription process 
leads to random mutation on the newly synthesized single strand DNA due to the poor 
proofreading capability of viral reverse transcriptase. These random mutations provide 
essential mechanism for virus to evolve and/or gain drug resistance. The single strand 
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DNA is later converted into double strand DNA through another round of reverse 
transcription. After the double strand DNA is generated, viral integrase binds with this 
viral double strand DNA and carries it into the host cell nucleus. Integrases also create a 
nick on host chromosome to facilitate the integration of viral DNA into host DNA and gaps 
are repaired by host cell DNA repair mechanism. The success of viral DNA integration 
marks the completion of HIV infection. Followed by the viral DNA integration, 
mechanisms of host cell DNA replication, RNA transcription and protein translation 
produce virus genomic materials and viral proteins. They are transported and gathered at 
cell membrane for virus packaging. Some viral enzymes can mediate these process. For 
example, viral protein Tat can transactivate transcription by binding the 5’ end of the viral 
DNA, resulting 1000 time increase of viral transcription (7).  
To generate functional virus particle, the HIV DNA firstly produce a pre-protein 
encoded by pr55, which will be digested to become functional elements. Similarly, 
Gag-Pol is also a pre-protein and can be digested into three functional enzymes: 
protease, integrase, and reverse transcriptase. Pre-protein Gp160 migrates to the cell 
membrane and is cleaved during the virion formation to form the envelope protein gp41 
and gp120. These proteins and host membrane proteins are incorporated on the plasma 
membrane to form viral envelope outside the capsid that contains the viral RNA genome. 
HIV particles are then assembled and released from host cells (8) (9) (10) (11).  
 
1.3. HIV pathogenesis 
There are two types of HIV, HIV type 1 and 2 (HIV-1, 2). There is limited knowledge 
about HIV-2, which has not been widely seen outside of Africa. Studies have shown 
striking similarities but also significant differences between the two. HIV-2 infection in 
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human host is characterized by lower transmission rates, longer asymptomatic stage, 
slower decline in numbers of CD4+ T lymphocytes and lower mortality rate (12-15). 
HIV-1 transmission occurs through exchange of body fluid from a virus carrier to an 
uninfected recipient. Body fluids that can pass HIV-1 virus include blood, semen, 
pre-seminal fluid, rectal and vaginal fluids, and breast milk. To transmit HIV, virus 
containing body fluids must contact with a mucous membrane or damaged tissue or be 
directly injected into the bloodstream. 
HIV enters CD4+ cells via its interactions with CD4 receptor and the chemokine 
coreceptors, CXCR4 or CCR5. Cells bearing CD4 and chemokine receptors are activated 
CD4 T lymphocytes, resting CD4 T cells, monocytes and macrophages, and dendritic 
cells.  
HIV infect cells mainly through two mechanisms. One is cell-free transmission and the 
other one is cell-to-cell transmission. In cell-free transmission, virus floats in plasma and 
infects T cells it encounters. In the cell-to-cell transmission, the virus is exchanged by 
direct cell contact between infected T cells and uninfected T cell.  
In the first 24 hours after infection, HIV infects dendritic cells within the mucous 
membranes and skin. Within five days, HIV infects dendritic cells and makes their way to 
the lymph nodes as well as peripheral blood where spreading viral replication ensues. In 
response to the viral antigen, CD4+ T lymphocytes are then recruited and migrate to 
lymph nodes where they become activated and proliferate with the help of 
pro-inflammatory cytokines (16). As the consequence, a suitable environment for viral 
replication is created (17). 
HIV infected cells have a shortened life span as a result of the virus infection (18) and 
immune system destruction occurs concomitantly. On the other hand, HIV infected 
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monocytes are more resistant to the toxicity of HIV (19). Thus, monocyte-macrophages 
act as reservoirs of HIV and effectors of tissue damage in organs such as the lung and 
brain. 
 
1.4. The immune response to HIV 
HIV infection leads to abnormality of immune system. Recent studies revealed 
immune responses may control HIV infection, although this defensive effect is mostly 
transient. These responses include humoral immune response, in which cytokines and 
antibodies are produced to prevent HIV infection, and cellular immune response, in which 
T cells are activated to enhance their cytotoxicity. Details are shown below.  
Cellular immune responses: At the early stage of HIV infection, CD4+ T cells 
decrease dramatically while CD8 T cells are activated and expanded up to 20 times 
higher. Activated CD4+ T cells promote maturation of CD8+ T cells, which possess 
specific and effective anti-HIV toxicity. A number of cytokines are secreted to enhance 
this cellular immune responses, such as interleukin-2 and interferon gamma. CD8+ T 
cells can also secrete chemokines to block the entry of HIV virus to host cells, such as 
CCR5 ligands RANTES (regulated on activation, normal T cell expressed and secreted), 
MIP-1 and CXCR4 ligand SDF-1. Notably, a clinical study identified a reverse correlation 
between level of these cytokines and HIV disease progression (20). 
Humoral responses: The humoral immunity includes B cells and their production of 
antibodies. Four to eight weeks after HIV infection, anti-HIV antibodies start to be 
generated. These antibodies mainly target viral envelope proteins. Thus cell-free virions 
are their main targets, although some antibodies may also destroy HIV-infected cells. 
Most antibodies cannot prevent cell to cell transmission of HIV. 
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As mentioned above, although immune response provide transient defensive 
mechanisms to control HIV infection, HIV may develop strategy to escape from these 
defensive immune response, such as antigenic variation (21) (22), decreasing surface 
MHC molecules expression as well as depleting CD8+ T cells, etc. (23). Another 
limitation of anti-HIV antibody is that virus is able to mutate their envelop protein to evade 
attack of antibodies and B-cells are not able to keep up with HIV antigens mutations 
speed. 
As more CD4 + T cells are eliminated with the infection progress, the CD4 T cell 
count keeps dropping. When it reaches below 200 cells/mm3 blood, the patient develop 
AIDS (24) (25). To obtain a better picture of disease progression, CD4/CD8 cell ratio 
should be monitored which has a normal ratio of about 1 to 1.5. If the disease is 
progressing, the CD4/CD8 ratio will be <1, indicating disease progression. 
 
1.5.  Antiretroviral therapy 
ART consists of a combination of drugs targeting the human HIV life cycle and act on 
different viral life cycle targets. It has led to profound decreases in morbidity and mortality 
rates in AIDS patient. It also provides effective treatment to prevent transmission from 
male to females and in men who have sex with men (26, 27). Inhibitors of HIV-1 reverse 
transcriptase and the viral protease, when used together, cause dramatic reductions in 
viremia. For many treated patients, plasma levels of HIV-1 RNA drop to less than the 
limits of detection as a result of ART treatment.  
ART fall into five classes: 1) nucleoside reverse transcriptase inhibitors (NRTI) and 
nucleotide reverse transcriptase inhibitors (NtRTI), 2) non-nucleoside reverse 
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transcriptase inhibitors (NNRTIs), 3) protease inhibitors, 4) entry inhibitors and 5) 
integrase inhibitors.  
Seven nucleoside/nucleotide analogs are Food and Drug Administration (FDA) 
approved HIV-1 drugs. NRTIs were the first medicines to be approved for the treatment of 
HIV. It stop HIV from replicating within cells by inhibiting the reverse transcriptase. NRTIs 
are analogues of the deoxynucleotides needed to synthesize the viral DNA. They 
compete with the natural deoxynucleotides for incorporation into the growing viral DNA 
chain. Once incorporated, these analogs stop following incorporation of deoxynucleotides 
into the DNA chain because of the absence of a 3’ OH group. The next incoming 
deoxynucleotide cannot form the next 5’–3’ phosphodiester bond needed to extend the 
DNA chain. Thus, when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted 
(28).  
While only one NtRTI, Tenofovir is currently approved at this time, they act very much 
the same way as NRTI (29). Nucleoside analogs are converted into nucleotide by 
undergo phosphorylation to become active by the body. Nucleotide analogues bypass 
this step, given that they are already chemically activated.  
Five NNRTIs are available on the market. The first NNRTIs was approved in 1996. It 
stop HIV replicating within cells by interfering with HIV's reverse transcriptase. Unlike 
NRTIs, NNRTIs are not incorporated into the viral DNA. Instead it inhibits reverse 
transcriptase by binding to an allosteric site of the enzyme (30). Since NNRTI-resistance 
mutations can emerge relatively quickly (31) (32), an NNRTI is generally used in 
combination with NRTIs.  
There are two types of entry inhibitor, Enfuvirtide and Maraviroc. Binding of viral 
envelope to its primary receptor CD4 is mediated by gp120, the surface subunit of the 
envelope. In its native form, the envelope glycoprotein is a heterotrimer of three gp120 
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molecules and three molecules of gp41 (33) (34). Binding to CD4 conformational 
changes gp120 and enable its binding to one of two chemokine receptors, CCR5 or 
CXCR4. Co-receptor binding allows the fusion peptide of the gp41 to insert into the target 
cell membrane, resulting in fusion of virus with the cell membrane (35). Maraviroc works 
by targeting CCR5 which located on human helper T-cells. The drug binds to CCR5, 
thereby blocking the HIV protein gp120 from associating with the receptor. Enfuvirtide is a 
peptide drug which must be injected to give. It acts by interacting with the N-terminal 
heptad repeat of gp41 of HIV to form an inactive hetero six-helix bundle, therefore 
preventing fusion of the virus with the host membrane (36). 
Currently, there are three integrase inhibitors. Integrase facilitates the interaction 
between viral DNA and a number of cellular cofactors which is indispensable for 
establishing the pre-integration complex (PIC) (37) (38). Upon the formation of the PIC, 
integrase remove a nucleotide from viral DNA exposes hydroxyl groups of its 3’ terminal. 
Subsequently, PIC enters the host nucleus and creates binding sites on host DNA by 
exposing its 5’ phosphate groups. This allows the viral DNA integrates into host DNA, 
which is also called strand transfer and is facilitated by integrase, followed by gaps repair 
(39). Integrase inhibitors disturb strand transfer process and therefore preventing the viral 
DNA from integrating into host DNA.  
FDA also approved 8 protease inhibitors. When cells are infected by HIV, they 
produce viral proteins for viral packaging. However, newly synthesized viral protein are 
not infectious unless they are cleaved by the vial protease. Protease inhibitors target viral 
protease and therefore block viral precursor from maturation. Notably, protease inhibitors 
are frequently used in combination with other categories of ART drugs to effectively treat 
HIV infection.  
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ART is now recommended for all adults with HIV infection. Recommended initial 
regimens include 2 NRTIs (abacavir/lamivudine (3TC) or tenofovir (TDF) disoproxil 
fumarate/emtricitabine (FTC)) and a third single or boosted drug, which should be an 
integrase inhibitor (dolutegravir, elvitegravir, or raltegravir), a NNRTIs (efavirenz (EFV) or 
rilpivirine) or a boosted protease inhibitor (darunavir or atazanavir) (40). 
The World Health Organization (WHO) published the leading recommendations for 
antiretroviral treatment in 2013. The favored recommendation is a fixed-dose 
combination of TDF; 3TC or FTC and EFV.  
It had been shown that the concentration of HIV-1 in plasma drops by impressive 
~99% in the first two weeks of ART treatment (41). New drugs with high potency, low 
toxicity and tolerability increase the feasibility of early initiated lifelong treatment. 
However, even with current ART regimens, HIV is not completely eradicated and 
virus is able to remain as a life-long infection due to its ability to stay hidden in restricted 
manner within infected blood cells. It is becoming clear that the viral reservoirs present a 
major obstacle to clear infection. 
 
1.6. HIV reservoir  
Many viruses have established mechanisms to escape from host immune 
surveillance through the process of natural selection (42). This persistence always 
involves viral reservoirs, on both cellular and anatomical level. In the mid-1990s, a series 
of reports showed the existence of provirus within latently infected resting life-long 
memory CD4+ T lymphocytes (2, 43) and these virus reservoirs, even after successful 
administration of ART, can produce infectious virus following cellular activation (44-46). 
Therefore HIV is able to remain a chronic life-long infection due to its ability to stay hidden 
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in cellular reservoirs. These reservoir cells contain the genetic code of HIV. Anatomical 
reservoirs of HIV are located throughout the body including the brain, lymphoid tissue, 
bone marrow, and the genital tract. 
In patients receiving ART, latent replication-competent HIV-1 provirus has been 
demonstrated in resting memory CD4+ T lymphocytes while low levels of virus can also 
be found in resting naïve CD4+ T cells (47). This latent reservoir, drives viral rebound 
once ART is stopped. It is established soon after primary HIV-1 infection (48) and can be 
activated by pro-inflammatory cytokines (49). The presence of HIV-1 in peripheral blood 
monocytes of patients with current ART treatment has also been demonstrated (50). 
 
1.7.  Macrophage viral reservoir 
In addition to HIV-1–infected CD4+ T cells, monocyte-macrophages may also be a 
key source of the viral reservoir in HIV-1–infected people. Macrophages are referred to 
as mononuclear phagocytes (MP) cells derived from circulating monocytes, and are 
terminally differentiated, non-dividing cells (51). They can be found in various tissues 
using different names (e.g. microglia in the brain, alveolar macrophages in the lung, or 
Kupffer cells in the liver) (51). MP are well known to phagocytose cellular debris and 
pathogens and act as antigen presenting cells (52). The life spans of the MP vary. 
Inflammatory macrophages die after a few days (53), whereas microglia or alveolar 
macrophages can live from several weeks up to years. MP are widely distributed in many 
different tissues and are able to infiltrate virtually all organs especially the brain, this 
make them a critically contributor to the spread of HIV in human body (54, 55).  
HIV in infected MP are more resistant to lentiviral replication’s cytopathic effects when 
compared with activated CD4+ T lymphocytes (56). Second, HIV has evolved 
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sophisticated mechanisms to prolong the life span of infected MP (57, 58). Therefore 
long-lived MP may harbor the virus for long period of time, thus constituting HIV 
reservoirs and posing a major obstacle to virus eradication from infected individuals. 
Mature HIV-1 can be found in intracellular vesicles of MP, suggesting macrophages’ 
ability to store HIV particles (59). Research showed that MP could store infectious HIV for 
weeks (60). 
Also, it has been shown that high molecular weight substances, including broadly 
neutralizing antibodies are excluded from the virus storing compartments (61, 62). HIV 
particles harboring in compartments like exosomes and microvesicles can also be 
released to facilitate and increase HIV dissemination (63). This may also contribute to 
HIV rapidly transfer from MP internal compartments to adjacent CD4+ T cells and 
uninfected monocyte-derived macrophage (MDM) (64, 65). In summary, MP make a 
prefect hideout for HIV particles, and growing evidence suggesting an important role of 
macrophages in the failure of the immune system to achieve HIV clearance within the 
acute and chronic phases of infection (Figure 2). Therefore, targeting delivery ART to 
monocytes/macrophages should be a powerful means to eliminate not only HIV but an 
opportunity to use the very mechanisms the virus uses to escape destruction. In this 
manner depots within MP can be ensured for drug depot and delivery.  
 
1.8.  ART MP delivery schemes  
MP are widely distributed in many tissues to recognize and clear altered and 
senescent cells, invading particulates, as well as macromolecular ligands via a multitude 
of receptors (66). This endocytosis/phagocytosis tendency of MP of foreign particles has 
provided an opportunity for the efficient delivery of therapeutic agents to these cells with 
the aid of carefully designed colloidal drug delivery systems. 
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To further take advantage of this property, nanoparticles have been designed to 
maximize macrophages uptake by altering nanoparticles physicochemical properties, 
which play a major role in its interaction with serum proteins and MP, as well as adding 
targeting ligands to the cell surface. The rate and the site of the uptake of the 
nanoparticles by MP are also influenced by the injected dose, blood flow and local tissue 
damage (67). 
Physicochemical properties of nanoparticle including size, charge, and shape which 
can have a very significant effect on the nanoparticles’ efficiency to target MP. In addition 
to controlling the physicochemical properties of nanoparticle to facilitate macrophages 
targeting, ligands can be incorporated into nanoparticle to specifically target monocytes 
and macrophages.  
Using a ligand targeting strategy has advantages of potentially increasing target 
specificity and avoiding the need for cationic lipids to trigger intracellular delivery. 
Successful homing of drugs to the target would help the nanoparticles to preserve its 
integrity, avoid interception by normal cells, penetrate interposing membranes, and 
reduce the drug dose and potential to diminish the side effects. 
In this section we highlight some approaches researchers have used to target MP for 
drug delivery and treat HIV disease. Identifying molecular targets within this cell 
population will help in creating new therapeutic solutions. A variety of ligands for 
macrophage targeting have been studied including peptides, antibodies, proteins, 
polysaccharides, glycolipids, glycoproteins, and lectins, which make use of mononuclear 
phagocytes characteristic receptor expression and phagocytic innate processes.  
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1.8.1. Peptides 
Cell targeting peptides and cell penetrating peptides have been used to achieve cell 
specific targeting and improve cell uptake. Tuftsin is a natural macrophage activator 
tetrapeptide (Thr–Lys–Pro–Arg) which is a part of the Fc-portion of the heavy chain of the 
leukophilic immunoglobulin G. This tetrapeptide is released after enzymatic cleavage as 
the free peptide fragment (68). Tuftsin is known to not only bind specifically to monocytes, 
macrophages and polymorphonuclear leukocytes, but also enhances their natural killer 
activity (69). These include potentiation of various cell functions, such as phagocytosis, 
pinocytosis, motility, immunogenic response, bactericidal and tumoricidal activities (69). 
Conjugating tuftsin onto the nanoparticles can not only homing the drug to macrophages 
but also to stimulate these cells non-specifically against infections (70). In one study, 
tuftsin were grafted on the surface of the drug-loaded liposomes which were given to 
Mycobacterium tuberculosis (MTB) infected animals twice weekly. Rifampin, an anti-MTB 
drug delivered for 2 weeks in tuftsin-bearing liposomes was at least 2,000 times more 
effective than the free drug in lowering the load of lung bacilli in infected animals (71). 
A short nicotinic acetylcholine receptor (AchR)-binding peptide 
(YTIWMPENPRPGTPCDIFTNSRGKRASNG) derived from the rabies virus glycoprotein 
(RVG) was used to target AchR expressed on macrophage/microglia surface. This 
peptide was fused to nona-D-arginine residues (RVG-9dR) to enable siRNA binding (72). 
SiRNA bond to RVG-9dR was able to induce gene silencing in wild type macrophages 
and microglia, but not in cells from AchR-deficient mice, confirming targeting specificity 
(72). Intravenous injection with RVG-9dR-complexed siRNA in mice reduced the 
lipopolysaccharide (LPS) induced TNF-α levels in blood as well as in the brain, leading to 
a significant reduction in neuronal apoptosis (72). These results demonstrate that 
macrophages targeting peptide RVG-9dR provides a platform for siRNA delivery to 
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macrophages and across blood brain barrier to microglia and that suppression of TNF-α 
can potentially be used to suppress neuroinflammation in vivo. 
Arginine-glycine-aspartic acid (RGD)-peptide has also been used to target integrin 
receptors expressed by monocytes (73). The interaction between the RGD domain on the 
integrin molecule and the integrin receptor on leukocytes stimulates phagocytosis by 
polymorphnuclear leukocyte (e.g.neutrophils) (74). In an ex vivo experiment using 
negatively charged uncoated and RGD-coated liposomes, amount of drug recovered 
from monocytes/neutrophils was 57.8±4.1% and 73.5±5.8% respectively (75). Also, 
RGD-coated magnetic liposomes brain levels of the drug was 1.5-fold compared to 
uncoated magnetic liposomes and 9.1-fold compared to free drug solution. Results 
clearly showed better localization of RGD-coated vesicles within these cells (75). 
 
1.8.2. Mannose 
C-type lectin receptors (CLRs) are pattern recognition receptors which are expressed 
by macrophages and dendritic cells, with highly conserved carbohydrate-recognition 
domains that bind sugar moieties (e.g., mannose, fucose, and glucan) on the surface of 
certain pathogens (76). The C-type designation is from their requirement for calcium for 
binding. Ligand recognition by CLRs leads to pathogen internalization via receptor 
mediated endocytosis. The pathogen is subsequently digested and presented as antigen 
to T cells in the context of major histocompatibility complex (MHC) class I or MHC II, or 
both. These receptors play numerous roles in immune function including antigenic 
recognition, endocytosis, antigen presentation and immune responses.  
The mannose receptor (MR) is a 175-kD C-type lectin type I transmembrane protein 
(77). Immune cells including alveolar macrophages, peritoneal macrophages, 
monocyte-derived dendritic cells, and Kupffer cells constitutively express high levels of 
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the MR. Macrophages and DCs can therefore be targeted via mannosylated 
nanoparticles which have been shown to preferentially target CLRs on macrophages and 
DCs repeatedly, resulting enhanced cellular uptake in vitro and in vivo. Mannosylation 
has been achieved by the incorporation of various ligands. A novel mannosylated 
cholesterol derivatives, 
cholesten-5-yloxy-N-(4-((1-imino-2-d-thiomannosylethyl)amino)butyl)formamide 
(Man-C4-Chol), as a ligand for mannose receptors was studied by several groups (78-80). 
Hasida and colleagues tried to deliver dexamethasone palmitate to alveolar 
macrophages with selective targeting of mannosylated liposomes via mannose 
receptor-mediated endocytosis after intratracheal administration. Dexamethasone 
palmitate incorporated in mannosylated liposomes (DPML) was extensively retained in 
alveolar macrophages compared with free drug (P < 0.001) and dexamethasone 
palmitate containing bare liposomes in LPS induced lung inflammation in rats. The 
anti-inflammatory effects of DPML in rats showed significantly inhibited tumor necrosis 
factor α, interleukin-1β etc in the lung (78). 
4-aminophenyl-α-d-mannopyranoside was conjugate to liposomes to deliver drugs to 
alveolar macrophages to study biodistribution (81) or to treat respiratory intracellular 
parasitic infections (82). The pulmonary administration and antibacterial activity of 
ciprofloxacin-loaded mannosylated liposomes against the intracellular bacteria were 
assessed. The antibacterial activity against various intracellular bacteria such as 
Chlamydophila pneumonia, Legionella pneumophila, Listeria monocytogenes and 
Francisella tularensis as estimated by pharmacokinetic (PK) and pharmacodynamic (PD) 
analyses was higher using liposomal systems (82). However, efficacy studies using the 
pathogens need to be performed to support the results. 
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Other mannose ligands used to target macrophages including alkylmannosides (83), 
Mann-His-C4-Chol (84) and Man2DOG (85).  
 
1.8.3. Antibody 
Antibody therapy has received wide attention due to its ability to selectively target 
cells through receptor-specific interactions (86). Antibody–nanoparticle conjugates have 
the potential to elicit effective active targeting and release of therapeutic targets at the 
disease site, while minimizing off-target side effects caused by dosing of normal tissues.  
Class II human leukocyte antigens (HLA) present antigenic peptides to regulatory T 
cells. Follicular dendritic cells (FDC), B lymphocytes, activated CD4+ T-cells and antigen 
presenting cells like macrophages are abundant in lymphoid tissues and all express 
substantial levels of the HLA-DR. Liposomes bearing surface-attached anti-HLA-DR 
antibodies make an interesting approach to target specifically HIV reservoirs as well as 
free HIV particles trapped in the FDC network. In one study, the ability of liposomes 
bearing anti-HLA-DR fragments at the end termini of PEG chains to target HLA-DR 
expressing cells was evaluated. Study showed that anti-HLA-DR bearing liposomes 
accumulated better in brachial and cervical lymph nodes than that of conventional 
liposomes upon a single subcutaneous injection. In contrast, other organs like liver did 
not show especially higher levels when compared to the unmodified liposomes (87). 
Growth factors produced by injured endothelial cells induce expression of vascular 
cell adhesion molecule-1 (VCAM-1) in monocytes/macrophages. Antiproliferative 
cyclopentenone prostaglandins (CP-PGs) are powerful anti-inflammatory agents, with the 
help of VCAM-1 antibody, one group developed a negatively charged liposome-based 
pharmaceutical formulation (LipoCardium) which direct CP-PGs towards the injured 
arterial wall cells of atherosclerotic mice. After 4 months in a high-lipid diet, all low-density 
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lipoprotein receptor-deficient control mice died from myocardium infarction or stroke in 
less than 2 weeks, whereas LipoCardium-treated mice even though still under high-lipid 
diet completely recovered from vascular injuries (88). 
 
1.8.4. Folic acid 
A vitamin, folic acid has recently emerged as a prominent targeting moiety capable of 
specific interaction with cells expressing the folate receptor (FR). FR consists of a high 
affinity (Kd ~ 10-9 - 10-10) folate binding protein attached to the membrane through a 
glycosylphosphatidyl-inositol anchor (89). Following binding of folate acid, rapid 
endocytosis delivers a fraction of the receptors into the cell (90). Importantly, covalent 
conjugation of protein, small molecules or even liposomes to folic acid does not alter its 
ability to bind the FR and undergo endocytosis (91); therefore, this makes folate acid a 
good targeting ligand to use to help drug enter cells by receptor-mediated endocytosis.  
FR expression is restricted to few cell types, including kidney and placenta, while 
normal tissues express low or undetectable levels of FR (92). There are three major 
forms of the FR, FR-α, FR-β, and FR-γ. The FR-α isoform is present primarily in placenta, 
kidney, malignant tumors and various cancer cell lines (89). FR-β is expressed in the 
placenta, monocytic and myelocytic lineages of hematopoietic cells and certain 
leukemias while there is negligible expression of this molecule on other blood cells such 
as lymphocytes, granulocytes, or erythrocytes (89). In contrast, it is difficult to find FR-γ, 
which is primarily a secreted isoform of hematopoietic origin under normal conditions 
(93). 
The feasibility of using FRβ to mediate the specific delivery of molecules is based on 
several unique biologic characteristics of the FR. Interestingly, very little folate conjugate 
is detected in blood cells or bone marrow after intravenous administration, cause FR-β 
20 
 
has been found to be functionally inactive although they can be easily detected by 
anti-FR-β antibodies (94). Recently, it has been reported that activated but not resting 
macrophages, possess a functionally active FR-β, thus FR as a marker of macrophage 
activation enables the facile labeling, isolation, and treatment of these inflammatory cells 
with folate conjugates (95).  
FR has been actively pursued to target nanocarriers to the site of inflammation for 
improved delivery and efficacy in arthritis and atherosclerosis (96, 97). In one study FA 
conjugated dendrimers was used to target macrophages and deliver methotrexate (MTX) 
as an antiinflammatory agent in a collagen-induced arthritis model in rats. The 
administration of FA- and MTX-conjugated dendrimer yields significant and beneficial 
protection from the inflammatory characteristics of collagen-induced arthritis (96). 
Anti-FRβ antibody was also used to target FRβ+ macrophages. A recombinant 
immunotoxin consisting of the truncated Pseudomonas exotoxin A conjugated to an 
anti-FRβ antibody has been reported to reduce the progression of atherosclerotic lesions 
in younger and older individuals (97). 
 
1.8.5. Other 
Acetylated low-density lipoprotein (AcLDL) is taken up by macrophages via 
scavenger receptors. One study investigated the delivery of AZT, an anti-HIV agent, to 
macrophages using AcLDL (98). Since the incorporation of AZT into AcLDL was found to 
be low, a prodrug was synthesized. Two cell lines expressing scavenger receptors were 
used to evaluate cellular uptake: J774.A (mouse macrophage) and U937 (human 
monocyte). A 10-fold increase was found with the AcLDL/prodrug as compared to the 
free drug. Moreover, addition of a 30-fold excess of AcLDL to the culture medium 
inhibited the uptake, confirming the specificity of the mechanism. The presence of excess 
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AcLDL was found to inhibit the cellular uptake of AcLDL/prodrug by macrophages while 
excess high density lipoprotein or low density lipoprotein was found to have little effect, 
suggesting that the AcLDL/prodrug complex is taken up into macrophages via the 
scavenger receptor (98). 
A more indigenous approach to macrophage targeting was adapted recently where 
the glucan shell of baker's yeast was used as a delivery vector to successfully ferry the 
cargo to the macrophages (99). The β1,3-D-glucan shells loaded with siRNA were 
successfully taken up by macrophages through dectin-1 receptor or other glucan 
receptor-mediated pathways upon oral delivery of nanoparticles containing as little as 
20 μg kg-1 siRNA directed against tumour necrosis factor α (Tnf-α). Its messenger RNA 
was depleted in macrophages recovered from the peritoneum, spleen, liver and lung, and 
lowered serum Tnf-α levels (99). 
 
1.9.  Inorganic nanoparticles 
In biomedical applications, progress in utilizing inorganic nanoparticles has advanced 
rapidly due to the extensive amount of work done in the synthesis and modification of the 
materials (100-103). The reasons being those inorganic nanoparticles provide a robust 
framework in which two or more components can be combined to give multifunctional 
capabilities. An example can be seen in polymer-coated superparamagnetic iron oxide 
nanoparticles. By conjugating multiple components such as drugs (104), tissue or cell 
targeting moieties, or siRNA (105) to the polymeric coating, not only can these 
multifunctional nanoparticles deliver drug to specific site, they can also be imaged inside 
the body by both magnetic resonance and fluorescence imaging, by conjugating 
fluorescent molecules.  
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Magnetic resonance imaging (MRI) is a powerful and non-invasive diagnostic 
techniques for living organisms based on the interaction of protons with the surrounding 
molecules of tissues. The current MRI contrast agents are in the form of either 
paramagnetic complexes like gadolinium (Gd3+) or manganese (Mn2+) chelates (106) or 
superparamagnetic iron oxide (SPIO) particles which exhibits superparamagnetic 
property (107). These contrast agents are used to increase the sensitivity of MRI for 
detecting various pathological processes. 
Paramagnetic complexes accelerate the longitudinal (T1) relaxation of water protons 
and therefore exhibit bright contrast in in T1 weighted MRI. Gadolinium 
diethylenetriaminepentaacetate has been the most widely used T1 contrast agent. In 
contrast, SPIO nanoparticles accelerate the transverse (T2) relaxation of water protons 
and exhibit dark contrast.  
To synthesize SPIO, several methods had been explored such as co-precipitation, 
microemulsion, thermal decomposition, and hydrothermal synthesis (108). Commercially 
used T2 contrast agents, such as Ferridex and Combidex, are synthesized via 
co-precipitation method, which involves the simultaneous precipitation of Fe2+ and Fe3+ 
species in aqueous media, and stabilized with hydrophilic polymers, such as dextran. 
SPIO synthesized by co-precipitation method are generally coated with hydrophilic 
polymers, making them highly stable under physiological conditions. However, they are 
generally polydisperse, poorly crystalline and limited in their capacity of drug loading and 
the drug dissociates rapidly after administration intravenously. 
Recently, SPIO synthesized by the thermal decomposition method have been 
extensively studied, as they are highly uniform, crystalline and size-controllable (109). 
These high quality hydrophobic iron oxide nanoparticles have been transferred to the 
aqueous phase using amphiphilic polymers, phospholipids, and silica shells. 
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1.10. Multifunctional Magnetic Nanoparticles 
Recently, techniques and procedures for producing monodispersed and 
size-controllable magnetic nanoparticles have advanced considerably which leads to very 
active explorations of the applications of magnetic nanoparticles, including biomedicine. 
Because of the potential benefits of multimodal functionality in biomedical applications, 
magnetic nanoparticles have been used to design and fabricate multifunctional 
nanoparticles. 
Currently, there are two strategies to fabricate magnetic nanoparticle-based 
multifunctional nanostructures (Figure 3). The first strategy, single magnetic nanoparticle 
functionalization, involves attaching drugs, antibodies, proteins and dyes to the surface of 
magnetic nanoparticles. The other method integrates the magnetic nanoparticles as well 
as other functional nanocomponents into polymer based nanoparticles, to achieve better 
stability and more functions. Because they can exhibit several features synergistically 
and achieve more than one function simultaneously, such multifunctional magnetic 
nanoparticles could have unique advantages in biomedical applications. 
For the application of the first strategy, Vancomycin-conjugated monodisperse 
iron-platinum (FePt) nanoparticles (FePt@Van conjugates) were manufactured. Bacteria 
at low concentrations are hard to detect and usually require long induction times before 
further analysis. FePt@Van conjugates can detect Gram-positive bacteria at exceptional 
low concentrations ∼101 cfu/mL via polyvalent ligand−receptor interactions (110). After 
mixing of FePt@Van conjugates with a solution of bacteria, the aggregation of bacteria 
can be observed by electron micrograph when external magnetic field applied in a very 
small area. The detection limit of this method is comparable to that of assays based on 
polymerase chain reaction (PCR), but this method is faster than when the bacterium 
count is low and is particularly useful when PCR is inapplicable. 
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Protein, genetic materials, organelles, and cells separation and purification is another 
way to use single multifunctional magnetic particles (111, 112). For example, using 
dopamine as a robust anchor, the successful synthesis of nitriloacetic acid 
(NTA)-terminated magnetic nanoparticles offers a simple and versatile platform for 
separating six histidine-tagged protein (113, 114). The target proteins cover the surface 
of the nanoparticles effectively and quickly, reducing the overall unoccupied surface area 
for nonspecific absorption of proteins thus achieving higher specificity than microparticles. 
Moreover, NTA-terminated magnetic nanoparticles can be used without pretreatment of 
the cell lysate and these nanoparticles are reusable without losing efficiency. 
For the application of the second strategy, in one study, drug delivery, cell targeting, 
magnetic manipulation, MRI and fluorescence imaging are simultaneously achieved 
using a multifunctional mesoporous silica nanoparticle (115). Mesostructured silica 
spheres were labeled with fluorescent dye and coated with hydrophilic groups to prevent 
aggregation. Water-insoluble anticancer drugs and SPIO were encapsulated inside and 
cancer-specific targeting agents were conjugated to the particle’s surface (115). The 
targeting ligand modification increased the drug payload delivery into human cancer cells 
relative to that into non-cancerous cells. The potential to simultaneously monitor and 
deliver molecules to the targeted tissue region will be highly beneficial for both imaging 
and therapeutic purposes. 
Hyeon and co-workers have manufactured a combination of magnetic nanoparticles 
and gold nanoshells to develop a novel nanomedical platform for diagnostic MRI and 
simultaneous photothermal therapy (116). Magnetic gold nanoshells (Mag-GNS) 
consisting of gold nanoshells embedded with magnetic Fe3O4 nanoparticles was 
fabricated (Figure 4). Amino-modified silica spheres were used to covalently attach 
Fe3O4 nanoparticles stabilized with 2-bromo-2-methylpropionic acid through a direct 
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nucleophilic substitution reaction between the bromo groups and the amino groups. Then 
gold nanoparticles were attached to silica spheres through residual amino groups. 
Eventually, gold nanoshells with embedded Fe3O4 nanoparticles were formed around the 
silica spheres, Anti-HER2/neu was also linked on the surface of the Mag-GNS resulting in 
the formation of the cancer cell targeting Mag-GNS. SKBR3 breast cancer cells targeted 
by these Mag-GNS were able to be detected by a clinical MRI system and selectively 
killed by near infrared (NIR) radiation. Especially, the targeted cancer cells were rapidly 
destroyed upon their short exposure to femtosecond laser pulses with an NIR wavelength 
and a low power compared to the use of a continuous laser (116). 
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FIGURE 1 DIAGRAM OF HIV MATURE VIRIONS 
The lipid bilayer is of cellular origin and includes aproximately 72 spikes of the viral 
Env glycoproteins and some cellular proteins. The principal structural proteins forming 
the core are p17, p24 and p7 (Figure is adapted from Sierra S et al, J Clin Virol. 2005 
Dec;34(4):233-44) 
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Drug Class    Generic Name (acronyms) 
 Nucleoside Reverse transcriptase Inhibitors (NRTIs) 
NRTIs block reverse 
transcriptase, an enzyme 
HIV needs to make copies of 
itself. 
 Abacavir (abacavir sulfate, ABC) 
 Didanosine (delayed-release didanosine, ddI) 
 Emtricitabine (FTC) 
 Lamivudine (3TC) 
 Stavudine (d4T) 
 Tenofovir disoproxil fumarate (tenofovir DF, TDF) 
 Zidovudine (azidothymidine, AZT, ZDV) 
 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
NNRTIs bind to and later 
alter reverse transcriptase  
 Delavirdine (delavirdine mesylate, DLV) 
 Efavirenz (EFV) 
 Etravirine (ETR) 
 Nevirapine (extended-release nevirapine, NVP) 
 Rilpivirine (rilpivirine hydrochloride, RPV) 
 Protease Inhibitors (PIs) 
PIs block HIV protease, 
an enzyme HIV needs to 
make functional viral 
proteins 
 Atazanavir (atazanavir sulfate, ATV) 
 Darunavir (darunavir ethanolate, DRV) 
 Fosamprenavir (fosamprenavir calcium, FPV) 
 Indinavir (indinavir sulfate, IDV) 
 Nelfinavir (nelfinavir mesylate, NFV) 
 Ritonavir (RTV) 
 Saquinavir (saquinavir mesylate, SQV) 
 Tipranavir (TPV) 
 Integrase Inhibitors 
Integrase inhibitors 
block HIV integrase, an 
enzyme HIV used to 
integrate its genome to 
host genome. 
 Dolutegravir (DTG) 
 Elvitegravir (EVG) 
 Raltegravir (raltegravir potassium, RAL) 
 Entry Inhibitors  
Entry inhibitors block 
HIV from entering CD4 cells. 
 Enfuvirtide (T-20) 
 Maraviroc (MVC) 
 
TABLE 1 SUMMARY OF ART APPROVED BY FDA  
(Data is from www.aidsinfo.nih.gov) 
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FIGURE 2 ROLE OF MACROPHAGES IN HIV-1 INFECTION AND DISEASE PROGRESSION 
The number of CD4+ T cells and viral genome copies in plasma during the different 
phases of HIV-1 infection are presented in a schematic drawing. The dotted lines indicate 
the effects of antiretroviral therapy. The contribution of macrophages to each phase of 
HIV-1 infection is indicated below the scheme. (Figure is adapted from Koppensteiner et 
al. Retrovirology. 2012 Oct 4;9:82) 
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FIGURE 3 TWO STRATEGIES TO FABRICATE MULTIFUNCTIONAL MAGNETIC 
NANOPARTICLES AND THEIR POTENTIAL APPLICATIONS 
(Figure is adapted from Gao J et al. Acc Chem Res. 2009 Aug 18;42(8):1097-107.) 
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FIGURE 4 THE SYNTHETIC APPROACH AND TEM IMAGES OF THE PRODUCTS IN EACH 
STEP 
a) Synthesis of the magnetic gold nanoshells (Mag-GNS). Transmission electron 
microscopy images of b) amino-modified silica spheres, c) silica spheres with Fe3O4 
nanoparticles immobilized on their surfaces, d) silica spheres with Fe3O4 and gold 
nanoparticles immobilized on their surfaces, and e) the Mag-GNS. (Figure is adapted 
from Kim J et al. Angew Chem Int Ed Engl. 2006 Nov 27;45(46):7754-8.) 
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2. Chapter II. SMART particle 
manufacture and 
characterization 
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2.1. Abstract 
Pharmacokinetics and pharmacodynamics study are the major factors that limiting the 
investigation of new nanoformulations. Multifunctional magnetite nanocarriers that 
integrate therapeutic agents into a single system have attracted considerable interest in 
theranostics integrating drug delivery and drug biodistribution. Using MRI to guide 
nanomaterial development can improve formulation development efficacy. To this end 
small magnetite ART (SMART) particle for treatment of HIV and simultaneously 
pharmacokinetics monitor were developed. We describe the fabrication of polymer 
nanocarriers co-encapsulating atazanavir (ATV), an HIV protease inhibitor, and 
magnetite nanoparticles which were synthesized by thermal decomposition method. 
Morphology of the SMART particles was studied by TEM. Drug loading were measured 
by high performance liquid chromatography (HPLC) and magnetite levels were measured 
by inductively coupled plasma mass spectrometry (ICP-MS). MDM uptake of SMART and 
ATV release of SMART from MDM was determined. Relaxivity of SMART in 
phosphate-buffered saline (PBS) and MDM was measured to make sure it is an efficient 
contrast agent for MRI. The relaxivity of SMART was found to be r2 = 6200.2 (s-1 ml mg-1) 
in MDM and r2 = 7052.1 (s-1 ml mg-1) in PBS. 
 
2.2.  Introduction 
Treatment for HIV is arduous due to its long duration and multidrug regimens. 
Eradication of the HIV-1 in its infected human host will necessitate antiretroviral drug 
delivery to viral sanctuaries with the secondary elimination of latent or restricted 
infections (117). Therefore, there is an increasing demand for the development of new 
compounds and screening of targeted formulation aiming at virus harboring cells. Among 
the virus harboring cells, we are particularly interested in macrophages, not only because 
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it is one of the major virus reservoirs, also because macrophage can serve as “Trojan 
horse” to store and deliver antiretrovius drug to other infected cells when treated with 
right particles. The right particles are the particles with size, shape and targeting ligand 
that macrophages prefers.  
Paul Ehrlich’s “magic bullet” concept reveals the possibility that targeted delivery of 
drug with the help of ligand having well defined affinity for specific cells. Normally drug 
delivery systems targeting cell type other than mononuclear phagocyte system are 
modified to prevent from phagocytosis. Numerous formulations have been developed to 
study and optimize their ability to escape monocyte/macrophage clearance. However as 
the role of monocytes and macrophages in infectious disease, inflammatory diseases and 
cancer is better understood, there is a growing interest in targeting these cell for 
therapeutically benefit. People gradually realized that phagocytosis process can be 
harnessed for targeting drug delivery and greater knowledge of the mechanisms of 
binding and uptake has been learned recently. This idea is especially valuable in 
treatment of HIV given the fact that macrophages harbor the virus. Macrophages express 
a wide range of receptors including FR, scavenger receptors, mannose receptors and 
Fc-receptors can be targeted using ligands appending particles.  
Targeting nanoparticles can facilitate drug delivery but, to achieve its potential, would 
require improved virus-target tissue drug bioavailability. Therefore, rapid noninvasive 
determination of targeted antiretroviral drug biodistribution is needed to study the targeting 
efficacy of targeting ligand in animal. One major hurdle towards achieving this goal is the 
dearth of any means to measure antiretroviral therapy distribution outside of plasma drug 
levels (118). 
Liposomes and polymer nanoparticles are the two major types of nanoparticles that 
have been developed and evaluated for diagnostic and therapeutic purposes. Liposomes 
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composed of natural lipids are attractive drug delivery systems because of their high 
biocompatibility, low immunogenicity, long systemic circulation and favorable 
pharmacokinetic profile. Specific targeted delivery can easily be achieved by conjugating 
a targeting ligand to the lipid molecule (119-121). Liposomal formulations including Doxil 
and DaunoXome are approved by FDA for clinical applications (120, 121). However, the 
possible intrinsic low drug loading capacity, fast release profiles of hydrophobic drugs 
and physical instability of liposomes limit their clinical applications of different drugs (122). 
Polymeric nanoparticles composed of synthetic polylactic-co-glycolic acid (PLGA) are 
another widely developed/studied drug delivery platform because of their high stability, 
relatively high drug loading capacity of all kinds of drugs, biodegradability, low toxicity, 
and controlled/sustained drug release profiles. Depending on particle composition, the 
drug release profiles of PLGA nanoparticles can be modulated to be within days, weeks 
or even months (123-125). However, the biocompatibility/immunogenicity of 
nanoparticles composed of synthetic polymers including PLGA is not as high as 
liposomes. Without further chemical modification, PLGA nanoparticles are rapidly 
removed from circulation by the MPS, resulting in short systemic circulation (122). In 
summary, both liposomes and PLGA nanoparticles are not independently structurally 
robust platforms. Thus, lipid-coated polymer nanoparticles, formed by combining 
synthetic polymers and natural lipids, have been developed as robust drug delivery 
platform to combine the advantages and avoid the disadvantages of liposomes and 
polymer nanoparticles (126).  
We theorized that one way to achieve this is by combinations of imaging agent and 
ART in a single nanoparticle. If realized, such multicomponent nanoparticle could permit 
rapid pharmacokinetic and pharmacodynamics evaluations of ART in virus-target tissues, 
such as the lymph nodes and brain. Recent years, SPIO nanoparticles also referred to as 
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magnetite have gained large attention due to its minimal toxicity profile and intrinsic 
superparamagnetic properties. The superparamagnetism magnetite exhibits make them 
respond to external magnetic field, which allow noninvasive tracking through MRI. 
Therefore we combined small magnetite and ART into a single nanoparticle and made 
SMART particle. By using the SMART particle, ART drug biodistribution would readily be 
quantitated by a conventional MRI scan. Such an approach would also provide the 
potential of delivering packaged medicines to sites of limited viral growth and serve, in 
part, to eliminate the viral reservoir. The approach was previously used for magnetically 
targeted cancer drug delivery utilizing T2- or T2*-quantification by MRI (127-130).  
To perform proof-of-concept studies we placed magnetite into lipid-coated PLGA 
nanoparticles with a commonly used antiretroviral protease inhibitor, ATV. The versatility 
of PLGA systems in terms of vesicle size, shape, composition and bilayer fluidity render 
them ability to incorporate a wide range of drugs and contrast agents like magnetite, and 
ability to carry cell-specific ligands (131). By combining PLGA, drug and magnetite, 
organic/inorganic hybrid composite biomaterials allowed drug distribution assessments 
with therapeutic ART delivery through a single MRI scan (132). SMART nanoparticles 
were screened for optimal uptake and retention in MDMs. This facilitated studies 
investigating the dynamics of in vivo drug tissue distribution. Collectively, the work 
provides the groundwork for the implementation of SMART systems for noninvasive drug 
PK for the inevitable goal of viral elimination.  
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2.3. Experimental Procedure  
2.3.1. Synthesis Of SPIO 
The magnetite particles were synthesized as follows: 6 mmol tris(acetylacetonato) 
iron(III) was mixed with 30 mmol 1,2-hexadecanediol, 18 mmol oleic acid, 18 mmol 
olylamine and 60 mL benzyl ether in a three-neck round-bottomed flask equipped with 
condenser, magnetic stirrer, thermograph and heating mantle and stirred under nitrogen. 
The mixture was slowly heated to 110oC and kept at that temperature for 1 hour, then 
slowly heated to 200oC. Reflux was kept after it reached 200oC for 2 hours, then slowly 
heated to 298oC and kept at reflux for another 1.5 hours. After cooling to room 
temperature, a dark homogeneous colloidal suspension was obtained. The suspension 
was precipitated in ethanol with a magnetic field. The black precipitate was dissolved in 
hexane with the presence of oleic acid and oleylamine and the solution was centrifuged 
at 3,800 x g for 10 min to remove any undispersed residue. The black solution was 
re-precipitated in ethanol and centrifuged at 10,000 x g for 30 min. Solid products were 
obtained by drying the precipitate under vacuum, generating the final dry particles. 
 
2.3.2. Preparation of SMART particle 
Preparation of the drug loaded 1,2-Distearoyl-sn-glycero-3-phosphorylcholine (DSPC) 
/mPEG-DSPE shell and PLGA core particle was as follows. First, a weighed amount of 
PLGA, ATV and magnetite were dissolved in chloroform (oil phase) with a weight ratio of 
magnetite to ATV of 1:3. Second, the aqueous phase was prepared by hydration of 
DSPC and mPEG-DSPE films. The oil phase was added to the DSPC and mPEG-DSPE 
aqueous solution drop-by-drop with constant stirring then sonicated for 60 seconds 
followed by a 20 second break under an ice bath. This procedure was repeated for three 
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cycles. Chloroform was then removed by stirring overnight. Third, the particle suspension 
was centrifuged at 500 x g for 5 min. The supernatant fluids were collected to remove the 
aggregated nanoparticles. A high speed 50,000 x g centrifugation for 20 min was used to 
collect the nanoparticles. After washing twice with PBS, the nanoparticles were 
resuspended. 
 
2.3.3. SMART size, surface charge and size distribution 
SMART size and size distribution were measured by dynamic light scattering (DLS, 
90Plus, Brookhaven Instruments Co. USA).The surface charge of the SMART particles 
was determined by ZetaPlus, a zeta-potential analyzer (Brookhaven Instruments Co. 
USA). The pH value and concentration of the particles dispersion were fixed before 
measurements of zeta potentials. 
 
2.3.4. Morphology of the SMART particles 
The shape and surface morphology of the SMART particles were investigated by 
transmission electron microscopy (TEM) performed as previously described (133). 
Samples were prepared from dilutions in distilled water of particle suspensions and 
dropped onto stubs. After air drying the particles were coated with a thin layer of gold 
then examined by TEM. The magnetic properties were determined by a Physical Property 
Measurement System. 
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2.3.5. SMART particle stability and release of drug in isotonic solution 
SMART particles were dispersed in PBS and placed into a 10 k dialysis tube in 2 L 
PBS under stirring at 37oC. At 30 min and 1, 2, 3, 4, 6, 8 and 10 days, 100 µl of the 
suspension was collected. The supernatant was dissolved in 100 µl tetrahydrofuran 
(THF)/methanol (volume ratio 1:10) mixture. The amount of ATV and magnetite was 
measured by high-performance liquid chromatography (HPLC) and ICP-MS, respectively 
(133, 134).  
 
2.3.6. Human monocyte isolation and cultivation 
Human peripheral blood monocytes were obtained by leukapheresis from HIV-1 and 
hepatitis seronegative donors and purified by counter-current centrifugal elutriation (135). 
The cells were cultured at a concentration of 1 × 106 cells/ml at 37oC in a humidified 
atmosphere (5% CO2) in DMEM supplemented with 10% heat-inactivated pooled human 
serum, 1% glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin and 1000 U/ml 
recombinant human MCSF for 7 to 10 days until differentiation into macrophages 
occurred. 
 
2.3.7. SMART uptake and retention by MDM 
After differentiation, MDM were treated with 100 μM SMART particles, based upon 
ATV content. Uptake of SMART particles was assessed without medium change for 8 
hours. Adherent MDM were collected by scraping into PBS, at 1, 2, 4 and 8 hours after 
treatment. Cells were pelleted by centrifugation at 500 x g for 8 min at 4°C. Cell pellets 
were briefly sonicated in 200 μl of methanol/acetonitrile (1:1) and centrifuged at 20,000 x 
g for 10 min at 4°C. To determine cell retention of SMART particles, MDM were exposed 
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to 100 μM SMART particles for 8 hours, washed 3x with PBS, and fresh media without 
particles was added. MDM were cultured for an additional 15 days with half medium 
exchanges every other day. On days 1, 5, 10 and 15 after SMART treatment, MDM were 
collected as described for cell uptake. Cell extracts were stored at -80°C until HPLC and 
ICP-MS analysis (133). 
 
2.3.8. Prussian blue staining of MDM retained SMART particles 
MDM were treated with 100 μM SMART particles for 24 hours. Adherent MDM were 
washed 3x with PBS. Cells were fixed with 2% formalin/2.5% glutaraldehyde in PBS for 
10 min then washed 2x with PBS. Fixed macrophages were treated with 5% potassium 
ferrocyanide/5% hydrochloric acid (1:1) for 10 min at room temperature. Following 
solution aspiration the cells were washed 2x with PBS. Stained cells were examined by 
light microscopy. 
 
2.3.9. MRI phantoms and relaxivity measures 
After differentiation, MDM were treated with 100 μM SMART particles, based upon 
ATV content. Twenty-four hours later the treatment medium was removed and the cells 
were washed 3× with 1 ml PBS. Cells were collected and suspended at different cell 
concentrations (0-5 x 106 cells/ml) in 1% agar gel. T2-relaxtivity was measured by MRI. 
Magnetite content in the cells was quantitated by ICP-MS.  
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2.4. Results 
2.4.1. Manufacture and characterization of SMART 
SMART were composed of a hydrophobic PLGA/ATV/magnetite core and an 
amphiphilic DSPC and DSPE-PEG2k lipid shell (Figure 5A). DSPC and DSPE-PEG2k 
increased SMART stability and facilitated increased systemic formulation circulation 
times. Both ATV and magnetite are distributed homogeneously within the core of the 
particle. SMART was made using a single oil-in-water emulsion with lipid surfactants. 
After sonication amphiphilic lipids self-assembled to the monolayer surrounding 
PLGA/ATV/magnetite containing oil droplets, achieved through hydrophobic interactions. 
Evaporation of chloroform under continuous magnetic stirring allowed for the formation of 
lipid-coated solid PLGA/ATV/magnetite core. SMART was then purified by 
ultracentrifugation before further characterization. DLS results showed that the average 
size of the particles is 268 nm with a polydispersity index (PDI) of 0.2. TEM was 
employed to obtain the image that best reflects SMART particle morphology (Figure 5B, 
right panel). This illustrated that the particles were spherical in shape with narrow size 
distributions. A representative particle is shown by TEM, showing the SPIO contained 
within the particle’s core. Our preliminary in vitro results showed that SMART is very 
stable and ATV can slowly release from SMART up to 10 days. 
 
2.4.2. SMART uptake, antiretroviral drug release and Prussian blue staining  
After SMART particle characterizations were completed, the in vitro kinetics of MDM 
uptake and retention were determined. Our previous studies of nanoformulated ART 
(nanoART) uptake in MDM showed that > 95% of total uptake occurs by 8 hours for ATV 
nanoART (136-138). Up to 2 μg of ATV/ 106 cells was recorded in MDM at 8 hours with 
magnetite uptake reflective of particle composition (Figure 5C). The majority of the cells 
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took up the magnetite as observed through Prussian blue staining (Figure 5D). Indeed, 
such staining demonstrated that magnetite-containing particles were readily incorporated 
in macrophages by 8 hours. The controlled and sustained release profile or ATV 
facilitates the application of the SMART particles for the delivery of antiretroviral drugs. 
 
2.4.3. Measures of SMART particle relaxivity  
Presence of SMART particles causing increased relaxivity (R2 (s-1)) in tissue as a 
function of concentration (expressed as mg/ml magnetite). Concentration dependent 
relaxivity [r2 (s-1 ml mg-1)] were determined using phantoms consisting of both free 
SMART particles (Figure 6A) and SMART particles taken up by MDM (Figure 6B). The 
magnetite concentrations in mg/ml contained by SMART in 1% agar gels were plotted 
against R2 as measured by MRI. The relationship between R2 and magnetite 
concentration of SMART in phantoms was linear within the range of the measured 
magnetite concentrations. The concentration dependent relaxivity of SMART was found 
to be r2 = 6200.2 (s-1 ml mg-1) in MDM and r2 = 7052.1 (s-1 ml mg-1) in PBS. The r2 of 
SMART in MDM was used for noninvasive in vivo quantitation of magnetite concentration 
due to SMART influx using MRI in next chapter.  
 
2.5. Discussion 
The principle goal in developing this polymer system rests in the ability to utilize MRI 
scans to rapidly assess cell and tissue drug biodistribution. The idea is that the 
polymer-encased dual magnetite and drug particle would permit a clear determination of 
drug levels in virus-target tissues in a very short time interval. However, a hybrid particle 
is hard to manufacture due to the different nature of the components. So it is important to 
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find the right composition. More magnetite will interfere with the incorporation of the ART 
drug, on the other hand, less magnetite will cause inefficient MRI signal. After testing 
different condition for drug release and relaxivity, we identified that the best drug vs 
magnetite ratio is 3:1, in which particles has slow drug release while has adequate 
magnetite to generate MRI signal. 
Our DLS results showed that the average size of the particles is 268 nm with a PDI of 
0.2. The narrow size distribution is linked to the DSPC, which serves to stabilize the 
polymeric SMART in the aqueous phase. The zeta potential of the particles is -45.2 mV, 
which provides its stability when suspended in aqueous media. Although DSPC is neutral 
when it is used as a particle coat it exhibits non-zero mobility in an external electric field. 
This may result in a higher negative charge since some anions bind to the neutral lipids 
making the surface more negatively charged.  
The magnetite showed as a solid black dot on TEM picture of the SMART particles 
(Fig.4 B). Not only it can be found inside the SMART, but also small amount of magnetite 
attached to the surface of the SMART particles. It may be free magnetite that were 
trapped in between the polymer.  
The relaxivity is an important factor to study a MRI contrast agent. Concentration 
dependent relaxivity of SMART in PBS and MDM showed slightly different result (7052 s-1 
ml mg-1 vs 6200 s-1 ml mg-1). It may be caused by the oxidization of magnetite during the 
24 hours incubation with MDM. The regression of relaxivity in PBS is better than that in 
MDM (0.998 vs 0.961). It’s possible that it’s hard for the cell to reach homogeneous 
suspension in 1% agar gel. 
The cell-based carriage and delivery of antiretroviral drugs to sites of active HIV-1 
replication can facilitate slow release of drug for time periods measured in weeks or 
perhaps months. As the monocyte-macrophage is a cell target for HIV growth, the added 
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benefit rests in the abilities to bring ART to subcellular sites of viral assembly. The next 
step would be to evaluate the correlation between magnetite and ATV after injected to the 
mice.  
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FIGURE 5 DEVELOPMENT OF SMART NANOPARTICLES 
(A) The schematic structure of lipid-coated PLGA SMART. ATV and SPIO are well 
distributed within the PLGA matrix to form the core of SMART. The PLGA core is coated 
with lipid monolayer to form the shell of SMART. (B) Representative TEM of a single 
SMART particle. (C) Time course of uptake (upper panel) and retention (lower panel) of 
SMART in MDM., MDM were treated with 100 µM SMART (based on ATV content) for 1, 
2, 4 and 8 hour uptake studies. For cell retention MDM were treated with 100 µM SMART 
for 8 hours, cell culture media was changed and cells were cultured for an additional 15 
days. The cell lysates at indicated times were analyzed by HPLC and ICP-MS for ATV 
and magnetite quantification, respectively. Data represent the mean ± SEM, n = 3, for 
each time point. (D) Prussian blue staining of MDM. MDM were treated with PBS 
(negative control, upper panel) or 100 µM SMART (lower panel) for 24 hours, and then 
fixed with 2% formalin/2.5% glutaraldehyde and stained with 5% potassium 
ferrocyanide/5% hydrochloric acid (1:1).  
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FIGURE 6 CONCENTRATION DEPENDENCE OF RELAXIVITY OF SMART 
Concentration dependence of relaxivity (r2) of SMART in (A) PBS and (B) MDM. MDM 
were incubated with 100 µM SMART (based on ATV content) for 24 hours. Collected 
MDM and SMART were suspended in 1% agar gel. T2 was measured by MRI and 
magnetite content by ICP-MS 
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3. Chapter III SMART: 
MRI-assayed drug and 
magnetite biodistribution 
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3.1.  Abstract 
The feasibility of imaging SMART biodistribution in vivo using MRI was investigated in 
this chapter. In this proof-of-concept study, the jugular vein was used for the intravenous 
injections of SMART and ensures uniform drug and magnetite distribution, minimizes 
standard deviation within groups and provides rapid particle distribution. The relationship 
between magnetite concentration and ATV concentration in different organs in different 
time points was evaluated. We demonstrated reduction of T2* caused by magnetite’s 
presence in tissues correlates with the drug content.  
The magnetite concentration was quantified from the change in T2 weighted relaxivity 
(R2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite relaxivity (r2) 
determined as the slope of magnetite concentration versus R2 in phantom studies. ATV 
concentrations was quantified by ultra performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) following the MRI scan.  
Our immunohistochemical analysis further demonstrates that SMART particles are 
taken up by liver and spleen macrophages. These cells serve as the reservoir of SMART 
particles, as well as the major targets of HIV. The advantages of using SMART rests as a 
cassette system for testing nanoparticles that direct nanoART to tissue viral reservoirs. 
 
3.2.  Introduction 
The visualization of cellular function in living organisms is not a new modality (139, 
140). Optical, X-ray, nuclear, MRI and ultrasound allows three-dimensional whole-body 
scans at high spatial resolution and are adept at morphological and functional evaluations. 
The data obtained can be enhanced by magnetite and improved image resolution. By 
immobilizing a specific target molecule on the surface of a magnetic particle, the 
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molecule inherits its magnetic property. Magnetic tissue targeting using multifunctional 
carrier particles can also facilitate effective treatments by enabling site-directed 
therapeutic outcomes.  
Our current work sought to use lipid coated PLGA SMART to encase magnetite and 
antiretroviral therapy to facilitate MDM uptake of drug and its subsequent slow release. In 
the last chapter we discussed the synthesis of SMART to facilitate drug screening for 
specific targeting ligands or sugars. In this chapter we are going to study the 
biodistribution of SMART and correlation between drug and magnetite concentration. A 
summary cartoon of the experiment scheme can be seen in Figure 7. We also stained the 
paraffin embedded tissue with Iba-1 antibody to label macrophages and Prussian blue to 
reveal iron in liver and spleen.  
 
3.3.  Experimental Procedures 
3.3.1. SMART biodistribution 
Biodistribution of SMART particles was determined in male Balb/cJ mice (Jackson 
Labs, Bar Harbor, ME). SMART particles at a dose of 30 mg/kg ATV were injected via a 
jugular vein cannula in a total volume of 100 μl for each mouse. The mice were scanned 
two hours before injection then continuously at 0.25, 1, 2 and 4 hours or at 24 hours after 
SMART administration. Tissues were collected following the final MRI scan. Tissue drug 
levels were quantitated by UPLC-MS/MS (141) and magnetite levels were determined by 
ICP-MS as previously described (134). 
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3.3.2. MRI acquisition 
MRI was acquired using a 7T/16cm Bruker (Ettlingen, Germany) Pharmascan 
MRI/MRS scanner and a commercial mouse body resonator. SMART detection by MRI 
was done using T2 mapping for quantitation and T2* weighted high resolution imaging for 
detection of biodistribution throughout the body. The sequence used for T2 mapping was 
a Carr-Purcell-Meiboom-Gill (CPMG) phase cycled multislice multiecho sequence. 
Forty-one 0.5 mm thick contiguous interleaved coronal images were acquired with an 
acquisition matrix of 256 x 192, 40 mm field of view, 12 echoes at 10 ms first echo time 
and 10 ms echo spacing, repetition time of 4680 ms, three averages, for a total 
acquisition time of 30 min. T2* weighted MRI was acquired using a 3D spoiled gradient 
recalled echo sequence with echo time = 3 ms, repetition time = 10 ms, 15 degree pulse 
angle, 50 x 40 x 30 mm FOV, 256 x 196 x 128 acquisition matrix, six averages, for a total 
scan time of 25min.  
 
3.3.3. MRI analyses 
T2 maps were reconstructed using custom programs written in Interactive Data 
Language (IDL; Exelis Visual Information Solutions, McLean, VA). Preinjection and 24 
hour postinjection maps were constructed using the even-echo images from the CPMG 
phase cycled imaging data set. Mean tissue T2 was determined using region of interest 
(ROI) analyses before and after SMART injection for the 24 hour results. Magnetite 
concentration was then determined from the change in relaxivity (R2 = 1/T2preinjection - 
1/T2postinjection) and the per milligram magnetite of SMART particle relaxivity (r2) determined 
as the slope of magnetite concentration versus R2 in phantom studies.  
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Acute (0-4 hour) data were acquired with in-magnet jugular vein injection, allowing 
sequential T2 mapping to be acquired with a T2* weighted fast low angle shot (FLASH) 
image acquired at the end of a four-hour period. The natural coregistration of these data 
allowed development of magnetite concentration maps based on relaxivity changes using 
custom programs written in IDL for the acute scanning session. The ROI analyses were 
performed using ImageJ (http://imagej.nih.gov/lj) software. For analysis of the acute 
study, the windows synchronize option was used to simultaneously draw ROIs at same 
locations on all concentration maps at different time points.  
 
3.3.4. Immunohistochemical identification of cell-SMART uptake 
To determine cell localization of SMART spleen and liver were collected after the final 
MRI scan and fixed in 10% neutral buffered formalin. Tissues were paraffin embedded 
and sectioned at 5 µm. To identify macrophages, sections were incubated with antibody 
to ionized calcium binding adaptor molecule 1 (Iba-1, Wako Chemicals USA, Inc., 
Richmond, VA). The polymer-based HRP-conjugated anti-mouse and anti-rabbit Dako 
EnVision were used as secondary detection reagents and color developed with 
3,3'-diaminobenzidine (DAB). All paraffin-embedded sections were stained with Prussian 
blue to identify magnetite content. Slides were imaged using a Nuance light microscopy 
system for brightfield imaging. 
 
3.4.  Results 
3.4.1. Real time SMART biodistribution and pharmacokinetics 
Magnetite labeling allowed the distribution of SMART particles to be quantified over 
time in live animals (Figure 8). Figure 8A shows examples of magnetite concentration 
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from magnetite in SMART, constructed from MRI T2 maps measured before and 
continuously every 30 minutes for four hours after SMART injection. ROI analyses of 
these data from six animals are shown in Figure 8B. A significant amount of the SMART 
is still within the vasculature, largely leading to the intensity in the kidney, as kidney 
shows very little uptake by 24 hours. This reflects the measured concentration in kidney 
reducing over the first four hours while in liver and spleen, organs where SMART 
accumulates, the mean signal is relatively constant or increases as the particles 
redistribute from the blood to the tissue. Significant accumulation of SMART was found in 
liver and spleen at 4 hours as can be appreciated in Figure 9.  
Figure 9 displays two of the 0.128 mm thick T2* weighted high-resolution 3D FLASH 
images of the same mouse before and 4 hours after injection of SMART. Presence of 
magnetite in tissue causes a reduction of T2* to the point of complete signal loss at TE = 3 
ms in the liver, spleen, and some abdominal regions. This method is not quantitative, 
however it does allow ready identification of the presence of magnetite throughout the 
body, which can be used to guide quantitative ROI analyses using T2 maps. 
 
3.4.2. Correlation between magnetite and drug tissue content 
Figure 10 shows the relationship between magnetite concentration and ATV 
concentration of liver, spleen and kidney in four animals 24 hours after injection. It can be 
appreciated that there is a significant positive correlation (Pearson Correlation, r=0.786, 
p=0.0008). These results demonstrate the capability of MRI to be used for monitoring 
nanoART distribution. 
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3.4.3. Identification of magnetite-ART relationships in systemic tissues 
We reasoned that cellular biodistribution of SMART was concordant with our prior 
results with nanoART (142). To prove this theory we next studied the relationships 
between SMART particle biodistribution and macrophages in mice following parenteral 
SMART injections. Animals were sacrificed 24 hours after injection and tissues were 
collected. Dual Iba-1 for macrophages and Prussian blue staining for magnetite were 
performed and evaluated by bright field microscopic imaging. Prussian blue staining was 
nearly exclusively in tissue cells identified as macrophages in liver. Spleen from mice 
without SMART treatment showed Prussian blue staining but staining increased when 
compared with mice received SMART treatment. As shown in Figure 11, Iba-1 positive 
macrophages were readily seen in both liver and spleen in parallel to distribution of 
Prussian blue. The dual staining pictures showed that the SMART particles were retained 
in tissue macrophages.  
 
3.5. Discussion 
The overarching idea of this chapter is to use SMART as a cassette system for testing 
ligands conjugated to particles for improved targeting of viral reservoirs such as the 
lymph nodes and brain. To this end, we selected DSPC and DSPE-PEG2k as the shell 
and PLGA as the core of SMART system. DSPC is used to increase the biocompatibility 
of SMART, and DSPE-PEG2k is used to build a sterically repulsive shield around SMART 
that reduces opsonization, prevents interactions with the MPS, escape renal exclusion, 
and increases systemic circulation. To the best of our knowledge, this is the first attempt 
to develop lipid-coated PLGA nanoparticles for HIV therapeutics.  
After pre-scan, mice were scanned by MRI continuously at 30 minute intervals up to 4 
hours after SMART administration. Magnetite levels in kidney, spleen and liver were 
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similar in the first half hour due to the magnetite is still circulating in the blood stream 
following SMART administration (Figure 8B). Yet as magnetite started to distribute over 
time, a higher amount stayed in liver and spleen after 4 hours of injection, correlated with 
higher concentration of magnetite in these organs at 24 hours as shown by the MRI 
scans. Our in vivo MRI results also showed that the concentrations of magnetite and ATV 
in mouse tissues, such as liver, spleen and kidney, correlate with one another at 24 h 
after injection.  
The results support the idea that SMART technology facilitates the noninvasive 
evaluation of drug PK and biodistribution in virus target tissues by MRI. These results 
demonstrate the capability of MRI to be used for monitoring ATV distribution by tracking 
the presence of magnetite in tissue, which causes a reduction of T2*. Our in vivo MRI 
results clearly demonstrated that SMART could facilitate the noninvasive evaluation of 
drug PK and biodistribution in different tissues and provide rapid assessments for the 
next generation cell and tissue ligand decorated particles.  
Erythrocyte hemoglobin and its breakdown products are a substantive source of iron. 
These are degraded after the lifespan of the erythrocyte (143). This occurs predominantly 
in the spleen with iron transferred back into the blood. The highly vascularized spleen 
contains easily seen red blood cell breakdown products including iron that are 
phagocytized by macrophages (144). Thus, the total iron content in the spleen is readily 
visualized by Prussian blue staining but substantively increased after SMART treatments 
(Figure 11 G and H). The iron content in spleen also changed from 228 µg/g before 
treatment to 356 µg/g after treatment, measured by ICP-MS.  
Notably, there is a considerable focus amongst HIV/AIDS researchers towards the 
development of reliable methods to bring drugs to reservoir sites with the explicit goal of 
eliminating virus. Targeted drug when combined with suitable imaging techniques like 
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SMART particles could facilitate this goal by providing a “go/no go” for treatment success. 
This technology clearly opens new opportunities to develop platforms that would 
accelerate elimination of viral infections.  
 
63 
 
A 
 
 
 
 
B 
C  
  
 
 
64 
 
FIGURE 7 CARTOONS OF SMART INJECTION AND BIODISTRIBUTION 
(A) MRI of mice were obtained and SMART was injected to mice through jugular vein. 
(B) SMART was taken up by MDM in vivo. (C) 24 hours later, MRI of mice were obtained. 
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FIGURE 8 MRI ASSESSMENTS OF THE TISSUE DRUG BIODISTRIBUTION AND 
PHARMACOKINETICS BY SMART PARTICLES 
MRI assessments of the tissue drug biodistribution and pharmacokinetics by SMART 
particles. After pre-MRI scan, mice were injected with SMART through a jugular vein 
cannula, and then scanned by MRI at continuously at 30 minute intervals up to 4 hours 
after SMART administration. Mean tissue SMART content was determined as detailed in 
Materials and Methods. Immediately after the final scan, mice were euthanized and 
tissues were collected for ATV quantification by UPLC-MS/MS. (A) MRI based images of 
magnetite concentration in kidney, spleen and liver from 0.5 h to 4 h following SMART 
administration. (B) Mean ± SEM (n=6) of magnetite levels in kidney, spleen and liver over 
4h following SMART administration. 
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FIGURE 9 3D GRADIENT RECALLED ECHO IMAGES OF THE SAME MOUSE BEFORE AND 
AFTER INJECTION OF SMART 
3D gradient recalled echo images of the same mouse before (A) and 4 hours after (B) 
injection of SMART. It can be appreciated that the signal from the liver is completely 
eliminated due to the accumulation of magnetite loaded SMART (L=lung, Lv=liver, 
K=kidney and S=spleen). 
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FIGURE 10 CORRELATION OF SMART-ASSOCIATED MAGNETITE AND ATV IN TISSUES 
24 HOURS AFTER ADMINISTRATION 
The magnetite concentration was quantified from the change in T2 weighted relaxivity 
(R2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite relaxivity (r2) 
determined as the slope of magnetite concentration versus R2 in SMART phantom 
studies. ATV concentrations were quantified by UPLC-MS/MS following the final 24 hour 
MRI scan. 
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FIGURE 11 IMMUNOHISTOLOGY OF IBA-1 STAINING AND PRUSSIAN BLUE STAINING 
Immunohistology of Iba-1 staining and Prussian blue staining of (A) Liver from control 
mice with Prussian blue (200×). (B) Liver from SMART treated mice with Prussian blue 
(200×). (C) Liver from SMART treated mice with Prussian blue and Iba-1 (200×). (D) 
Enlargement from indicated section in C. (E) Spleen from SMART treated mice with 
Prussian blue (200×). (F) Spleen from SMART treated mice with Prussian blue and Iba-1 
(200×). (G) Enlargement from indicated section in F. (H) Spleen from control mice with 
Prussian blue and Iba-1 (400×). Livers and spleens were fixed with 10% formalin, paraffin 
embedded and sectioned for immunohistological analysis after the final MRI scan. 
Macrophages were identified by Iba1 stains (brown) and magnetite identified by Prussian 
blue. Fl=lymphoid follicle, M=marginal zone. 
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4. Chapter IV APM and FAPM 
manufacture and 
characterization 
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4.1. Abstract 
Dextran-based SPIO nanoparticles have been extensively used clinically as MRI 
contrast agents. These dextran-based SPIO nanoparticles are taken up by phagocytic 
cells and accumulate in the reticuloendothelial system. These nanoparticles can be 
utilized for multifunctional biomedical applications with simultaneous drug-delivery and 
imaging capabilities. However, dextran coating is not strongly associated with SPIO 
nanoparticles and can be readily detached, leading to SPIO aggregation and precipitation 
under physiological conditions (145). Also, the lack of functional groups on the surface of 
PLGA nanoparticles for covalent modification has limited their potential for surface 
tethering targeting ligands (146). Additionally, these dextran-based SPIO nanoparticles 
are limited in their capacity of drug loading and the drug dissociates rapidly after 
administration intravenously (147). 
In this study, we describe the development of single magnetite nanoparticles with 
strong polymer coating for MRI. The developed nanoparticles are composed of a 
hydrophobic 10 nm magnetite core and a PEG coating, anchored with a bisphosphate 
drug, Alendronate (ALN). The study was designed to investigate the characteristics and 
biodistribution of the developed SPIO. Size, shape, charge, morphology, relaxivity and 
stability of ALN-PEG coated magnetite (APM) and ALN-PEG-folate coated magnetite 
(FAPM) were evaluated. 
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4.2. Introduction 
Significant reductions of residual HIV from its cell and tissue reservoirs in brain, 
lymphoid tissues, bone marrow, gastrointestinal and the genital tracts can be achieved by 
chemical or immunological means. One way to achieve this goal is through viral 
reservoir-targeted long-acting antiretroviral nanoparticles by monocyte-macrophage drug 
targeting (148). To facilitate such an end, a number of ligands for macrophage targeting 
are being developed and include peptides (68), antibodies (87), proteins and sugars (78) 
that make use of cell-specific receptor expression or by enabling phagocytosis. An 
additional hurdle towards achieving this goal is the dearth of ways to measure ART 
distribution outside of plasma drug levels (118).  
In particular pharmacokinetic and pharmacodynamics studies have recently 
demonstrated the benefit of such targeting strategies; although assessments of such 
drug biodistribution improvements have entailed intensive tissue analyses (149). We 
posit that such processes can be improved further by targeting ligand testing of linked 
magnetic nanoparticles and parallel MRI evaluation of particle distribution. Moreover, we 
theorize that such results would closely mimic drug tissue biodistribution.  
Prior magnetite platforms have been developed for this purpose (150-152). Among 
them, polysaccharides are the most widely studied coating materials for magnetite 
(153-155). However, the potential in vivo coating disassociation and bare magnetic 
particle exposure causing cellular toxicity are of significant concern (156). Another 
limitation of current coating materials for magnetite is the complicated conjugation 
strategies or limited appreciated functional groups for specific ligand decoration in 
magnetite. Substantive efforts have been made to resolve these issues. ALN is a 
bisphosphonate drug, which is clinically used to treat osteoporosis. The P-C-P structure 
of bisphosphonates is known for its ability to bind divalent metal ions, such as Ca2+ (157). 
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Taking advantages of this metal binding ability, we successfully conjugated ALN into 
polymers for stable magnetic particle coating. FA is a targeting ligand of FR, which 
expression is restricted to few cell types including macrophages. FA was successfully 
decorated to the exterior coating of magnetite to allow comparisons of magnetite 
biodistribution with and without targeting.  
 
4.3. Experimental Procedures 
4.3.1. Synthesis of magnetite  
The magnetite particles were synthesized as follows: 6 mmol tris(acetylacetonato) 
iron(III) was mixed with 30 mmol 1,2-hexadecanediol, 18 mmol oleic acid, 18 mmol 
olylamine and 60 ml benzyl ether in a three-neck round-bottomed flask equipped with 
condenser, magnetic stirrer, thermograph and heating mantle and stirred under nitrogen. 
The mixture was slowly heated to 110oC and kept at that temperature for 1 hour, then 
gradually heated to 200oC. Reflux was kept after it reached 200oC for 2 hours, then slowly 
heated to 298oC and kept at reflux for another 1.5 hours. After cooling to room 
temperature, a dark homogeneous colloidal suspension was obtained. The suspension 
was precipitated in ethanol with a magnetic field. The black precipitate was dissolved in 
hexane with the presence of oleic acid and oleylamine and the solution was centrifuged 
at 3,800 x g for 10 min to remove any undispersed residue. The black solution was 
re-precipitated in ethanol and centrifuged at 10,000 x g for 30 min. Solid products were 
obtained by drying the precipitate under vacuum, generating the final dry particles. 
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4.3.2. Synthesis of alendronate conjugated polyethylene glycol (ALN-PEG) 
Polyethylene glycol monomethyl ether 5,000 (mPEG5k) (1 g, 0.2 mmol) was 
dissolved in anhydrous dichloromethane (5 mL) together with 4-dimethylaminopyridine 
(12 mg, 0.1 mmol) and triethylamine (101 mg, 1 mmol). The mixture was cooled to 0°C, 
and p-toluenesulfonyl chloride (Tos-Cl) (0.191 g, 1 mmol) was added. Next, the mixture 
was incubated overnight at room temperature and the mixture precipitated in ether. The 
precipitate (crude product) was purified using a LH-20 column with methanol as the 
eluent. The yield of p-toluenesulfonyl-terminated mPEG5k (Tos-PEG) was 65%. 
Tos-PEG (0.52 g, 0.1 mmol) was dissolved in dimethylformamide (5 mL). Sodium azide 
(65 mg, 1 mmol) was then added. The reaction proceeded with stirring at 100°C for 1 day. 
After filtration and solvent removal, the crude product was dissolved in dichloromethane 
and precipitated into ether. The precipitate (crude product) was further purified using a 
LH-20 column with methanol as the eluent. The yield of azide-terminated PEG5k 
(azido-PEG) was 70%.  
Azido-PEG (0.25 g, 0.05 mmol) and 1-hydroxy-4-pent-4-ynamidobutane-1, 
1-diyldiphosphonic acid (40 mg, 0.1 mmol) were dissolved in an ethanol-H2O solution 
(1/1 v/v, 2 mL). Sodium ascorbate (19.8 g, 0.1 mmol) and copper sulfide pentahydrate 
(2.5 mg, 10 μmol) were then added separately under argon. The reaction mixture was 
stirred for 3 days at room temperature. After removal of the solvent, the crude product 
was acidified and purified using a LH-20 column with methanol as the eluent. The yield of 
the ALN conjugated polyethylene glycol (ALN-PEG) was 70%. 
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4.3.3. Synthesis of FA conjugated ALN-PEG (ALN-PEG-FA) 
Alendronate sodium trihydrate (1g, 3 mmol) was dissolved into 5 ml water, the pH 
was adjusted to around 8.0 with NaOH, Fmoc-PEG5k-N-hydroxysuccinimide (NHS) (0.5 
g, ~ 1 mmol) was then slowly added into ALN solution. The reaction solution was stirred 
overnight at room temperature, and then dialyzed to remove excess ALN. After 
lyophilization, the resulting ALN-PEG-Fmoc powder (0.35 g) was directly dissolved in 
20% piperidine in THF and reacted at room temperature for 2 hours to deprotect Fmoc. 
The solvent was concentrated using rotavapor under vacuum, and precipitated into ether. 
The resulting precipitate (ALN-PEG-NH2) was further purified with dialysis and 
lyophilization.  
FA (110 mg, 0.25 mmol) was dissolved in 2 ml DMSO plus 50 ul of triethylamine. A 
1.1 molar ratio of NHS (31 mg) and N,N’-dicyclohexylcarbodiimide (DCC; 57 mg) was 
added. The mixture was stirred 4 hours at room temperature in the dark. The by-product, 
dicyclohexylurea, was removed by filtration. ALN-PEG-NH2 (0.25 g) was then added into 
the NHS-folate solution for overnight conjugation at room temperature in the dark. The 
crude product was precipitated with diethylether, and further purified by dialysis.  
CF633-NHS (1umol) and ALN-PEG-NH2 (10 mg) were dissolved in 0.5 ml 
dimethylsulfoxide (DMSO), and then reacted overnight in dark at room temperature. The 
resulting CF633-labeled ALN-PEG was purified using a LH-20 column with methanol as 
the eluent. 
 
4.3.4. Coating of ALN-PEG and ALN-PEG-FA onto magnetite (APM and FAPM) 
To synthesize APM, various amount of ALN-PEG polymer (5, 10, 20, 50 mg) was 
dissolved in 0.5 ml deionized water separately; 5 mg magnetite was dissolved in 10 ml 
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THF. Polymer solution was added slowly to magnetite THF dispersion with stirring. The 
mixture was stirred overnight, and then THF was removed using rotary evaporator. The 
crude product was dissolved in 5 ml deionized water, and then centrifuged at 500 x g for 
10 min to remove uncoated magnetite. Non-coated polymer was removed by dialysis 
using 25k dialysis tubing overnight. After dialysis, the dispersion was lyophilized to obtain 
APM. The mass ratios between magnetite and coating materials were measured using 
thermal gravimetric analysis (TGA).  
To synthesize FAPM, 16 mg ALN-PEG polymer and 4 mg ALN-PEG-Folate were 
dissolved in 0.5 ml deionized water and 5 mg magnetite was dispersed in 10 ml THF. 
Polymer solution was added slowly to the magnetite THF dispersion with stirring in the 
dark. The mixture was stirred overnight, and then THF was removed using a rotary 
evaporator. The crude product was dissolved in 5 ml deionized water, and then 
centrifuged at 500 x g for 10 min to remove uncoated magnetite. Non-coated polymers 
were removed by dialysis using 25k dialysis tubing overnight in dark. After dialysis the 
dispersion was lyophilized to get FAPM powder.  
CF633-labeled APM and FAPM were synthesized using the same procedure with 2 
mg CF633-labeled ALN-PEG dissolved in the polymer solution. 
 
4.3.5. Physicochemical and stability characterization of APM and FAPM  
Particles size and size distribution were measured by DLS using a Malvern Zetasizer 
Nano-ZS instrument (Malvern Instruments Inc., Westborough, MA, USA). The pH value 
and concentration of the particles dispersion were fixed before measurements of particles 
size and size distribution. All measurements were performed at 25°C. The shape and 
surface morphology of the APM and FAPM particles were investigated by TEM 
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performed as previously described (158). Samples were prepared from dilutions in 
distilled water of particle suspensions and dropped onto stubs. After air-drying the 
particles were then examined by TEM. The stability of APM was studied in NaCl solutions 
(1M and 2M) and buffer solutions with pH 2, 4, 6, 7.4, 8, 10, 12 that were determined by 
DLS and TEM. Concentration dependent relaxivity (r2 s-1 ml mg-1) was measured by MRI 
of APM or FAPM dispersion in concentrations ranging from 0 µg/ml to 40 µg/ml.   
 
4.3.6. Statistical analyses 
The data are presented as mean ± SEM. Statistical significance between groups was 
assessed using Student’s t-test by Graph-Pad® Prism unless specified. The data were 
considered statistically significant if P<0.05. 
 
4.4. Results 
4.4.1. Synthesis of ALN conjugated polyethylene glycol (ALN-PEG) and FA 
conjugated ALN-PEG (ALN-PEG-FA) 
As an initial step towards securing this end, we manufactured ALN-PEG and 
ALN-PEG-FA polymers. These were synthesized for magnetite coating. In order to 
efficiently conjugate hydrophilic ALN to PEG polymer, the versatile click reaction was 
used (Figure 12A). 
mPEG was first tosylated with toluenesulfonyl chloride, then converted to azido-mPEG 
under reflux using excess sodium azide. To introduce an acetylene group onto ALN, 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride/NHS was used to 
conjugate ALN and pentynoic acid. Finally, these two fragments were successfully 
conjugated together through copper (I)-catalyzed Huisgen 1, 3-dipolar cycloaddition 
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between the azide and alkyne with high yield at room temperature. ALN-PEG-FA was 
synthesized using amidation strategy (Figure 12B). First, ALN was incorporated into PEG 
by reaction with Fmoc-PEG-NHS, and the Fmoc was then deprotected with piperidine to 
synthesize amine functionalized ALN-PEG (NH2-PEG-ALN) for ligand conjugation, which 
is one of the most attractive properties of ALN-PEG polymers. For folate conjugation, 
NHS-activated folate was reacted with NH2-PEG-ALN to synthesize the targeted 
ALN-PEG-FA with high yield. From 1H NMR spectrum, emergence of the singlet peak of 
1,2,3-triazole at 8.32 ppm verified the successful conjugation of ALN to PEG polymer 
(Figure 12C)  
 
4.4.2. Manufacture of APM and FAPM 
To confirm the strong coating ability of ALN-PEG polymer to magnetite, oleic acid (OA) 
coated magnetite synthesized by thermal decomposition method with an average size in 
10 nm were selected for replacement coating. The OA coating material is hydrophobic 
and relatively weakly bound to the core of magnetite. OA-coated magnetite was 
dispersed into THF, then ALN-PEG was added into this solution for replacement coating 
overnight at room temperature and turned the magnetite from hydrophobic to hydrophilic. 
At the end of replacement, THF was evaporated and magnetite particles were 
redispersed in water and dialyzed. After dialysis, the dispersed solution was lyophilized. 
The structure of APM and FAPM is demonstrated in Figure 13.  
Benefitting from its high coating efficacy, ALN-PEG was coated onto magnetite in a 
programmable and reproducible manner. Up to 100% of the ALN-PEG was coated onto 
magnetite as measured by TGA (Figure 14C). We chose magnetite with 20% wt 
magnetite and 80% wt polymer for further evaluation due to its outstanding stability and 
ability to conjugate sufficient number of ligand molecules.  
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To demonstrate the potential of APM as one novel nanomedicine platform for 
targeting ligand evaluation and optimization, FA was selected to conjugate to the 
ALN-PEG polymer (ALN-PEG-Folate) using amidation strategy (Figure 12Figure 12). For 
the preparation of folate-decorated magnetite, OA-coated magnetite was dispersed into 
THF, and then ALN-PEG and ALN-PEG-Folate (weight ratio 4:1) were added into this 
solution for OA replacement overnight at room temperature. The purification procedures 
were same to preparation of APM. 
 
4.4.3. Physicochemical and stability characterization of APM and FAPM  
The lyophilized particles are easily dispersed in water and the nanoparticles are very 
stable in biological buffers such as PBS. Under an external magnetic field, APM retained 
its dispersion stability in PBS while OA-coated magnetite in PBS were colloidally unstable, 
precipitated, and were attracted towards a magnetic field within minutes (Figure 14A). To 
study the stability of APM, we tested its size and PDI in acidic, basic and high ironic 
strength conditions. APM nanoparticles were very stable in various conditions, and there 
was no significant increase in size and PDI of APM within the 2 weeks’ timeframe of the 
study (Figure 15A). After one month storage on the shelf, APM solutions were clear and 
no nanoparticles precipitate out (Figure 15B). The TEM pictures of APM nanoparticles 
also confirmed this result (Figure 15C). After two month storage, all APM solutions 
remained clear expect APM nanoparticles in NaCl 2M solution precipitated out slightly 
(Figure 15B), which was easy to form stable dispersion again with gentle shaking. 
The structure of FAPM is illustrated in Figure 13B. The size of APM and FAPM 
nanoparticles was assessed by TEM showing that the iron oxide core is morphologically 
indistinguishable from each other, with a mean particle size of 10 nm (Figure 14B). 
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Concentration dependent relaxivity [r2 (s-1 ml mg-1)] causing increased relaxivity (R2 
(s-1)) in tissue as a function of concentration (expressed as mg/ml magnetite) of APM and 
FAPM is an important parameter. To investigate the MR signal enhancement effects, the 
relaxivity of aqueous magnetite particles at different magnetite concentrations was 
determined using a 7T MRI scanner. The magnetite concentrations in mg/ml were plotted 
against R2. As shown in Figure 14D, the relaxivity of both APM and FAPM varied linearly 
with the magnetite concentration. The relaxivity of FAPM was found to be r2 = 582 (s-1 ml 
mg-1) and of APM r2 = 638 (s-1 ml mg-1) (Figure 14D). The r2 values of these particles were 
used for noninvasive in vivo quantitation of magnetite concentration using MRI.  
CF633-labeled APM and FAPM were synthesized successfully, SPIO coated with 
CF633 conjugated ALN-PEG polymer, with CF633 conjugated ALN-PEG and 
ALN-PEG-Folate polymer and with oleic acid visualized by UV light (254 nm) exposure 
(Figure 16). Only the SPIO with CF633 label showed fluorescence suggesting a 
successful dye conjugation. 
 
4.5. Discussion 
HIV-1 infected memory effector CD4+ T cells and in more limited numbers, tissue 
macrophages, are targets for persistent low-level infection (56, 159). Both are refractory 
to immune and chemical elimination and are resistant to virus-associated cytopathicity 
(56). HIV-1 has evolved mechanisms to prolong the life span of infected cells (57, 58). 
Virus is present for long periods of time in gut, lymphoid and brain reservoirs thus 
constituting obstacles for viral eradication within infected individuals (160). One way to 
reduce residual virus in its reservoirs is by targeted antiretroviral nanotherapy (136, 149, 
161). Nonetheless, adequate targeting schemes have not yet been achieved and current 
methods to develop them are commonly slow and cumbersome. To such ends our own 
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works have centered on ways to bridge classic PK evaluation with MRI assessment of 
particle distributions (158). 
FA has emerged as an important targeting moiety capable of specific interaction with 
cells expressing the FR. Its expression is restricted to a few cell types, including 
mononuclear phagocytes lineage and is regulated by cell activation that is initiated by the 
particle itself. Specific drug targeting can thus parallel tissue sites of infection and 
consequent inflammation along with the reticuloendothelial system. MP and 
reticuloendothelial cells would then serve as drug storage depots (136, 137). This, 
notably, makes FA conjugation specifically for antiretroviral therapeutic nanoparticles of 
particular benefit for treatment of HIV infection (162).  
In this study, FA was successfully conjugated to the ALN-PEG polymer, which has 
high metal binding affinity. Magnetite with ALN-PEG coating or ALN-PEG and 
ALN-PEG-Folate coating showed similar size, shape and relaxivity (Figure 15) which 
demonstrates that conjugation of FA doesn’t compromise the stability of the nanoparticle. 
Relaxivity of both particles had an excellent regression, and the similar result (582 s-1 ml 
mg-1 vs 638 s-1 ml mg-1) is critical to make the magnetite concentration comparable.  
APM demonstrated excellent stability in various buffers (Figure 15A, B, C), no 
nanoparticles precipitate out after one month storage on the shelf. After 2 months of 
storage, all APM dispersions remained stable except APM nanoparticles in the 2 M NaCl 
solution where some precipitation was observed which can be reversed with gentle 
shaking. The strong binding ability of ALN polymer contribute significantly to the 
prolonged shelf life. 
We have manufactured a single magnetite particle that is easy to conjugate targeting 
ligands, the other potential targeting ligands includes mannose, antibody and peptides. 
We posit that the targeting ability of different ligands can be studied further by targeting 
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ligand testing of linked magnetic nanoparticles and parallel MRI evaluation of particle 
distribution. Moreover, we theorize that such results would closely mimic drug tissue 
biodistribution with the same targeting ligands.  
 
88 
 
 
 
 
 
89 
 
 
 
 
 
 
C
  
 
90 
 
 
FIGURE 12 ALN-PEG AND ALN-PEG-FOLATE POLYMER SYNTHESIS 
(A) Synthesis of ALN-PEG polymer. (B) Synthesis of ALN-PEG-Folate polymer.  
(C) 1H NMR spectrum of ALN-PEG polymer. 
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FIGURE 13 THE SCHEMATIC STRUCTURE OF APM AND FAPM 
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FIGURE 14 APM AND FAPM CHARACTERIZATION 
(A) APM and OA coated magnetite under external magnetic field. (B) TEM of APM 
and FAPM in PH=7.4 solution. (C) TGA analysis of magnetite with various polymer 
coatings. (D) Relaxivity of APM and FAPM.  
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FIGURE 15 APM STABILITY 
(A) Size and PDI of APM in various conditions for 14 days. (B) APM in various 
conditions after one or two month storage. (C) TEM of APM in various conditions after 
one month storage. 
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FIGURE 16 SPIO COATED WITH DIFFERENT VISUALIZED BY UV LIGHT EXPOSURE 
SPIO coated with CF633 conjugated ALN-PEG polymer (left), CF633 conjugated 
ALN-PEG and ALN-PEG-Folate polymer (middle) and oleic acid (right) visualized by UV 
light (254nm) exposure  
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5. Chapter V APM and FAPM 
biodistribution analyzed by MRI 
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5.1. Abstract 
In this proof-of-concept study, biodistribution of APM and FAPM in male Balb/cJ mice 
were evaluated. The magnetite concentration was quantified from the change in T2 
weighted relaxivity (R2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite 
relaxivity (r2) determined as the slope of magnetite concentration versus R2 in relaxivity 
studies.  
To this end, we made SMART nanoparticles to rapidly assess ART tissue 
biodistribution. SMART testing previously demonstrated near equivalence in drug 
biodistribution and PK amongst MRI and drug tissue measurements. Herein, we have 
taken this work a step further by demonstrating the utility of FA decoration to facilitate ART 
targeting. FAPM improved entry and particle retention to the reticuloendothelial system 
over replicate untargeted formulations. The feasibility of imaging APM and FAPM 
biodistribution in vivo using MRI was investigated in this chapter. We posit that MRI 
testing can predict drug biodistribution, and that the value of targeted magnetite is of 
immediate benefit towards the rapid assessment of biodistribution for enhanced drug 
tissue concentrations in viral reservoirs in the quest for chemical eradication of HIV 
infection.  
Our immunohistochemical analysis further demonstrates that APM and FAPM 
particles are taken up by liver and spleen macrophages which serve as the reservoir of 
these particles, as well as the major targets of HIV.  
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5.2. Introduction 
Regimen adherence, systemic toxicities and limited drug penetrance to viral reservoirs 
are obstacles limiting the effectiveness of long-term antiretroviral therapy. The 
development of monocyte-macrophage-targeted nanoART, while providing opportunities 
to simplify drug dosing regimens, has proved more limited for its abilities to improve drug 
penetrance into viral cell and tissue reservoirs. Research progress was slowed by the 
extensive time needed to complete pharmacokinetic, pharmacodynamics and 
biodistribution testing of nanoART efficacy. We have developed APM and FAPM platform 
(158). Their biodistribution would readily be quantitated by a conventional MRI scan to 
reflect the targeting ability of the ligand (127, 163).  
Our previous studies demonstrated that FR are expressed in differentiated 
macrophages, as cell lysates were probed with antibodies to FR1 and FR2 (FRβ) and 
showed that FRβ but not FR1 is expressed and localized to the cell membrane. 
Engagement of the FR receptor in enhancing FA-coated nanoART uptake was 
demonstrated by the ability of free FA to block enhanced FA-nanoART uptake. Our in 
vitro studies have demonstrated that the administration of nanoART stimulated the 
expression in the FR receptor in macrophages (164).  
NanoART with or without the FA targeting ligand were injected into mice to confirm 
the usefulness of magnetite to assess ART biodistribution. Such a system can provide a 
relevant screening platform and could be used to investigate a broader range of targeting 
systems for delivery of nanoART to reservoir sites of viral infection.  
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5.3. Experimental Procedures 
5.3.1. Manufacture and characterization of FA-P407-ATV/r 
Manufacture of nanoATV/r was prepared as described before (165). FA-P407 was 
synthesized and used to manufacture FA-nanoATV/r (149). For preparation of FA-P407 
ATV and FA-P407-RTV, FA-P407 (0.2% w/v) and P407 (0.3% w/v) were mixed in 10 mm 
HEPES to generate micelles; 1% (w/v) drug was added and mixed overnight. For 
preparation of P407-ATV and P407-RTV, 0.5% (w/v) P407 was mixed with 1% drug. The 
suspensions were homogenized at 20,000 PSI using an Avestin Emulsiflex C3 
homogenizer (Avestin Inc, Ottawa, ON, Canada) until the desired particle size (300–400 
nm) was reached. Free polymers and non-encapsulated drug particles were removed by 
centrifugation; the nanoparticles were resuspended in 0.2% P407. The resulting 
nanosuspension was lyophilized and stored in a desiccator protected from light. Drug 
loading was determined using reversed phase HPLC and UPLC-MS/MS as described. 
Particle size, PDI and zeta potential for the nanoformulations were determined by 
dynamic light scattering using a Malvern Zetasizer Nano-ZS instrument (Malvern 
Instruments Inc., Westborough, MA, USA). 
 
5.3.2. Biodistribution of APM and FAPM  
Biodistribution of APM and FAPM was determined in male Balb/cJ mice (Jackson 
Labs, Bar Harbor, ME) after 2 weeks on folate deficient diet (Harlan Teklad TD.00434, 
Harlan Laboratories, Indianapolis, IN). Twenty-four hours before administration of 
magnetite particles, mice were injected with LPS (Sigma-Aldrich St. Louis, MO) at 2 
mg/kg dose intraperitoneally, or injected with 100 mg/kg nanoparticle-based RTV 
boosted ATV coated with poloxamer 407 (nanoATV/r), intramuscularly. APM or FAPM (2 
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mg iron/kg wt) were injected intravenously in a total volume of 100 µl for each mouse. 
The mice were scanned by MRI before and 24 hours after APM or FAPM injection.  
 
5.3.3. MRI acquisition and analyses 
MRI was acquired using a 7T/16cm Bruker Pharmascan MRI/MRS scanner (Ettlingen, 
Germany) and a commercial mouse body resonator. Magnetite detection by MRI was 
done using T2 mapping for quantitation and T2* weighted high resolution imaging for 
detection of biodistribution throughout the body. The sequence used for T2 mapping was 
a CPMG phase cycled multislice multiecho sequence. Forty-one 0.5 mm thick contiguous 
interleaved coronal images were acquired with an acquisition matrix of 256 x 192, 40 mm 
field of view, 12 echoes at 10 ms first echo time and 10 ms echo spacing, repetition time 
of 4680 ms, three averages, for a total acquisition time of 30 min. T2* weighted MRI was 
acquired using a 3D spoiled gradient recalled echo sequence with echo time = 3 ms, 
repetition time = 10 ms, 15 degree pulse angle, 50 x 40 x 30 mm FOV, 256 x 196 x 128 
acquisition matrix, six averages, for a total scan time of 25min.  
T2 maps were reconstructed using custom programs written in Interactive Data 
Language (IDL; Exelis Visual Information Solutions, McLean, VA). Preinjection and 24 
hour postinjection maps were constructed using the even-echo images from the CPMG 
phase cycled imaging data set. Mean tissue T2 was determined using ROI analyses 
before and after magnetite injection for the 24 hour results. Magnetite concentration was 
then determined from the change in relaxivity (ΔR2 = 1/T2preinjection - 1/T2postinjection) and the 
per milligram magnetite particle relaxivity (r2) determined as the slope of magnetite 
concentration versus R2 in phantom studies. The ROI analyses were performed using 
ImageJ (http://imagej.nih.gov/lj) software.  
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5.3.4. PK of FA-nanoATV/r 
Male Balb/cJ mice (Jackson Labs), 4-6 weeks old, were maintained on 
folate-deficient diet for 2 weeks then injected with 50 mg/kg of nanoATV/r or FA 
conjugated nanoATV/r (FA-nanoATV/r). The mice were sacrificed on day 7. Mice with 
LPS treatment received LPS (2 mg/kg) 24 hours before receiving drug and were 
sacrificed on day 14. The mice were injected with either 50 mg/kg of nanoATV/r or 
FA-nanoATV/r. Tissues were collected and stored at -80oC. Tissue drug levels were 
determined using UPLC-MS/MS as previously described (166). 
 
5.3.5. Immunofluorescence  
Immunofluorescence staining of magnetite particles was determined in male Balb/cJ 
mice (Jackson Labs) after 2 weeks on folate deficient diet. Twenty-four hours before 
administration of magnetite particles, mice were injected intraperitoneally with LPS at 2 
mg/kg, or injected with 100 mg/kg nanoATV/r, intramuscularly. CF633-labeled APM or 
CF633-labeled FAPM (2 mg iron/kg wt) was injected intravenously in a total volume of 
100 µl for each mouse. After 24 hours, tissues were collected following the MRI scan for 
immunofluorescence staining. 
Preparations of whole-mount tissues and frozen sections: tissues were collected after 
whole mouse perfusion with PBS and fixed in 10% neutral buffered formalin for 24 hours, 
then incubated in 15% and 30% sucrose for cryoprotection and embedded in optical 
cutting temperature compound (OCT) (Tissue-Tek) at −20 °C. For whole-mount staining, 
tissues were cut to 20 µm on a cryostat. Tissues were carefully harvested from melting 
OCT. Immunofluorescence staining of frozen sections: sections were 
blocked/permeabilized in Tris Buffered Saline with Tween (TBBS) containing 10% normal 
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goat serum, and stained with rabbit monoclonal antibody against Iba-1 (1:500; Wako 
Chemicals, USA) and mouse monoclonal antibody against FRβ (a generous gift of Dmitry 
Dmitrov, National Cancer Institute, Bethesday, MD) (1:200) for 1 hour at room 
temperature. Primary antibodies were labeled with secondary goat anti-mouse for FRβ 
antibody and anti-rabbit antibodies for Iba-1 conjugated to the fluorescent probes Alexa 
Fluor 488 and Alexa Fluor 594, and nuclei were labeled with 
4′,6-diamidino-2-phenylindole (DAPI). Images were acquired with a Nikon swept field 
confocal microscope (Nikon). 
 
5.3.6. Statistical analyses 
The data are presented as mean ± SEM. Statistical significance between groups was 
assessed using Student’s T-test by Graph-Pad® Prism unless specified. The data were 
considered statistically significant if P < 0.05. 
 
5.4. Result 
5.4.1. MRI acquisition and analyses 
Our previous studies showed that administration of nanoART activated macrophages 
and stimulated the overexpression of FR in vivo (149). For the evaluation of the 
biodistribution of non-targeted APM and macrophage-targeted FAPM, and their 
localization within macrophages in mice, the immune system of mice was first activated 
with LPS or nanoATV/r, and then APM or FAPM were administered via intravenous 
injection. The APM and FAPM biodistribution were determined by MRI. Figure 17A 
displays 0.128 mm thick T2* weighted high-resolution 3D FLASH images of the same 
mouse before and 24 hours after injection of APM or FAPM. Presence of magnetite in 
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tissue causes a reduction of T2* causing signal loss in proportion to concentration at TE = 
3 ms in the liver, spleen, and some abdominal regions.  
 
5.4.2. Biodistribution of APM and FAPM  
APM (n=6) and FAPM (n=6) biodistribution in LPS or nanoATV/r treated mice were 
quantified from regions of interest in MRI T2 maps (Figure 17B and C). It can be 
appreciated that in animals treated with LPS, FAPM showed a higher accumulation in 
various tissues compared to APM (2.49 vs 0 µg/ml for renal pelvis, 5.49 vs 0 µg/ml for 
renal cortex, 10.94 vs 2 µg/ml for spleen and 26.26 vs 10.48 µg/ml for liver) (Figure 17B) 
In animals treated with nanoATV/r, FAPM also showed more accumulation in various 
tissues compared to APM (1.02 vs 0 µg/ml for renal pelvis, 0.69 vs 0 µg/ml for renal 
cortex, 13.07 vs 5.79 µg/ml for spleen and 17.27 vs 7.53 µg/ml for liver) (Figure 17C). 
FAPM accumulated more in various tissues, which demonstrated its targeting ability to 
FR on activated tissue macrophages, and showed the potential of APM and FAPM for 
assessing image-guided drug PK and BD.  
To further confirm this concept, biodistribution of nanoATV/r or FA-nanoATV/r was 
evaluated in Balb/cJ mice with or without LPS activation. The mice were injected with 
either 50 mg/kg of nanoATV/r or FA-nanoATV/r, and the drug concentrations in different 
tissues were quantified by UPLC/MS-MS. The tissue ATV concentrations following 
treatment with FA-nanoATV/r were significantly higher than with nanoATV/r and were 
found to be dose dependent. A 50 mg/kg FA-nanoATV/r dose gave 1.82 μg/g and 208 
ng/g ATV concentrations in liver and spleen, respectively, compared to 439 ng/g and 145 
ng/g in liver and spleen following nanoATV/r treatment in LPS-treated mice (Figure 18 A). 
Alternately, the ATV tissue concentrations following FA-nanoATV/r were 2.93 μg/g and 
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86.3 ng/g compared to 146 ng/g and 2.36 ng/g for nanoATV/r in liver and spleen, 
respectively in mice treated only with nanoATV/r (Figure 18 B). 
 
5.4.3. Immunofluorescence  
To confirm the in vivo FR-targeting ability of FAPM, the colocalizaiton of magnetite 
particle and FR was also studied by administration of CF633-labeled APM and FAPM 
(CF633-APM and CF633-FAPM) to mice. Mouse FRβ antibody and Iba-1 antibody were 
used to determine colocalization. These were used to detect FR and macrophages. 
Results obtained by immunofluorescent staining clearly showed co-localization of FRβ 
FRβ and Iba1 in spleen from mice injected with LPS and nanoATV/r, in agreement with 
the hypothesis that activated macrophages express FRβ. In addition, CF633-labeled 
FAPM were mainly detected in Iba-1+/FR+ cells (Figure 19A and B).  
 
5.5. Discussion 
Figure 17A displays 0.128 mm thick T2* weighted high-resolution 3D FLASH images 
of the same mouse before and 24 hours after injection of APM or FAPM. Presence of 
magnetite in tissue causes a reduction of T2* causing signal loss in proportion to 
concentration at TE = 3 ms in the liver, spleen, and some abdominal regions. The 
shortening in the T2* value correlates with the signal intensity decrease as a result of the 
strong magnetite susceptibility effects. As a result, tissues containing magnetite appear 
darker in post scans demonstrating higher accumulation of FAPM systemically in both 
LPS and nanoATV/r pre-treated mice. This method is semi-quantitative, however it does 
allow ready identification of the presence of magnetite throughout the body, which can be 
used to guide quantitative ROI analyses using T2 maps.  
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Prussian blue staining of tissue sections was also performed in liver and spleens of 
FAPM treated animals, but showed discordant results. One potential confounding factor 
is that the oxidation of magnetite during perfusion and tissue processing could prevent 
the success of Prussian blue staining. It is also possible that the ultra small size of the 
magnetite results in staining that is undetectable. 
In conclusion, we observed parallel patterns of tissue biodistribution between 
nanoATV/r or FA-nanoATV/r and APM and FAPM in treated mice. Notably, these 
comparable distributions of ATV and magnetite concentrations confirmed the ability of our 
ALN-PEG coated magnetite system to be used as a targeting ligand approach to predict 
actual drug PK and tissue BD. Future direction includes replacing FA with other 
macrophages targeting ligands. Cancer targeting ligands can also be tested in this 
platform.  
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FIGURE 17 APM AND FAPM BIODISTRIBUTION 
(A) 3D gradient recalled echo images of the same mouse before (pre) and 24 hours 
after (post) injection of APM or FAPM. APM and FAPM biodistribution in renal pelvis, 
renal cortex, spleen and liver, quantified by T2 MRI in (B) LPS or (C) nanoATV/r treated 
mice. Data are presented as mean±SEM, *P < 0.05 considered significant using 
Student’s t-test.  
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FIGURE 18 NANOATV/R AND FA-NANOATV/R BIODISTRIBUTION IN KIDNEY, SPLEEN 
AND LIVER AS QUANTIFIED BY UPLC-MS/MS 
These are shown for nanoATV/r in (A) LPS and (B) nanoATV/r treated mice. Data are 
presented as mean±SEM, *P < 0.05 considered significant using Student’s t-test. Panel A 
and B are days 7 and 14, respectively.  
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FIGURE 19 IMMUNOFLUORESCENCE STAINING OF FAPM BIODISTRIBUTION 
Immunofluorescence staining of FAPM biodistribution in LPS treated mouse spleen 
(top) or nanoATV/r treated mouse spleen (bottom), 200x. (A) phase contrast, (B) DAPI, 
(C) IBA-1, (D) folate receptor, (E) magnetite (arrow indicates individual magnetite) and (F) 
merge. 
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6. Chapter VI Discussion 
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There is a considerable focus amongst HIV/AIDS researchers towards the 
development of reliable methods to bring drugs to reservoir sites with the explicit goal of 
eliminating virus. HIV-1 is present for long periods of time in gut, lymphoid and brain 
reservoirs thus constituting obstacles for viral eradication within infected individuals (160). 
One way to reduce residual virus in its reservoirs is by targeted antiretroviral nanotherapy 
(136, 149, 161). A hurdle towards achieving this goal is the dearth of ways to measure 
ART distribution outside of plasma drug levels (118). In addition, adequate targeting 
schemes have not yet been achieved and current methods to develop them are 
commonly slow and cumbersome. To such ends our own works have centered on ways 
to bridge classic PK evaluation with MRI assessment of particle distributions (158). 
Taken together, we have developed a polymer system rests in the ability to utilize 
MRI scans to rapidly assess cell and tissue drug biodistribution. SMART particles is 
polymer-encased dual magnetite and drug particle which is hard to manufacture due to 
the different nature of the components. So it is important to find the right composition. 
More magnetite will interfere with the incorporation of the ART drug, on the other hand, 
less magnetite will cause inefficient MRI signal. After testing different condition for drug 
release and relaxivity, we identified that the best drug vs magnetite ratio is 3:1, in which 
particles has slow drug release while has adequate magnetite to generate MRI signal. To 
increase the biocompatibility of SMART, we used DSPC and DSPE-PEG2k as the shell 
of SMART system. To increase drug loading, we used PLGA as the core. To the best of 
our knowledge, this is the first attempt to develop lipid-coated PLGA nanoparticles for HIV 
therapeutics.  
During the first 30 mins of SMART administration, magnetite levels in kidney, spleen 
and liver were similar due to the magnetite is still circulating in the blood stream. As 
magnetite started to distribute, a higher amount stayed in liver and spleen after 4 hours of 
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injection, correlated with higher concentration of magnetite in these organs in 24 hours 
MRI scan. Our in vivo MRI results also showed that the concentrations of magnetite and 
ATV in mouse tissues, such as liver, spleen and kidney, correlate with one another at 24 
h after injection.  
The results support the idea that SMART technology could facilitate the noninvasive 
evaluation of drug PK and biodistribution in virus target tissues by MRI. Also it 
demonstrates the capability of MRI to be used for monitoring ATV distribution by tracking 
the presence of magnetite in tissue which causes a reduction of T2*. Targeted drug when 
combined with suitable imaging techniques like SMART particles could facilitate this goal 
by providing a “go/no go” for treatment success. This technology clearly opens new 
opportunities to develop platforms that would accelerate elimination of viral infections.  
Another polymer based magnetite system (APM) is also developed for non-invasive 
biodistribution study of targeting ligand conjugated nanoparticle. FA is capable of specific 
interaction with cells expressing the FR. As FR expression is restricted to a few cell types, 
including kidney epithelial cells and mononuclear phagocytes lineage (92) and 
expression is regulated by cell activation as present in disease specific targeting of drug 
can parallel tissue sites of infection and inflammation along with the reticuloendothelial 
system which could then act as a drug storage depot (136, 137). This, notably, makes FA 
conjugation specifically for antiretroviral therapeutic nanoparticles of particular benefit for 
treatment of HIV infection (162).  
We have manufactured a single magnetite particle that is easy to conjugate targeting 
ligands with, the other potential targeting ligands includes mannose, antibody and 
peptides. We posit that the targeting ability of different ligands can be studied further by 
targeting ligand testing of linked magnetic nanoparticles and parallel MRI evaluation of 
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particle distribution. Moreover, we theorize that such results would closely mimic drug 
tissue biodistribution with the same targeting ligands.  
Future direction includes decorating magnetite with other macrophages targeting 
ligands or even CD4+ T cells ligands. These potential ligands include HIV gp120-derived 
peptides (e.g. CKGIRIGPGRAVYAAE), CCR5-targeting RANTES fragments, hyaluronic 
acid, mannose derivatives, and combinations of those ligands. 
Targeting ligand with highest accoumlation in viruse reversior found by MRI scanning 
will be used to conjugate NanoART particles. Currently NanoART is composed of ATV or 
RTV which is not a WHO recommended first line HIV drug. Usage of the first line HIV 
treatment for nanoart is promising. NRTIs like 3TC and abacavir, or entry inhibitor 
maraviroc are good candidates to incorporate into nanoart to extend drug half-life and 
increase bioavailability. NanoART composed of the novel prodrugs and their 
combinations can also be prepared using homogenization. Formulations of optimal 
physical characteristics will be determined from particle size, charge, PDI and drug 
loading capacity to ensure rapid uptake by targeted cells and drug potency. These 
nanoART with new drugs can be coated with targeting ligands found by magnetite system 
to further facilitate immune responses and promote clearance of virus from cellular 
reservoirs. Targeting formulation vs non-targeting formulation uptake by targeted cells 
will be tested to evaluate targeting efficiency of the ligand.  
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